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Abstract 
 
Breast cancer is prevalent both in the United States and worldwide. While both screening tests 
and targeted therapies are available, there are still challenges in the diagnosis, prognosis, and treatment 
of breast cancer. We were motivated to develop a new approach for both studying the etiology of 
heterogeneity in breast cancer phenotypes and predicting the course of disease in tumor biopsies using 
an emerging chemical imaging technology. 
 
It has been described extensively that the tumor microenvironment, or stroma, can promote or 
suppress cancer phenotypes in many tissues. We hypothesized that interaction with fibroblasts, the 
predominant cell type found in the breast tumor stroma, is a critical regulatory step in the progression 
of breast cancer from confined to invasive disease. Hence, we developed a novel three-dimensional co-
culture model to investigate this interaction. The development and validation of this model is described 
in chapter two. We used it first to determine how cancerous molecular signatures can propagate from 
cancerous to normal epithelium through the activation of fibroblasts. Changes in the architectural 
morphology of normal mammary acini were used as a metric to determine cancer progression, in 
addition to gene expression analysis and cell-based assays such as proliferation and migration assays. 
This system is a robust and easily applied tool for investigating fibroblast-epithelial communication in a 
physiologically-relevant context.  
 
The 3D co-culture system was used to investigate how fibroblasts impact the growth of estrogen 
receptor-positive (ER+) breast cancer cells and this is described in chapter three. ER+ is the most common 
subtype of breast cancer (>75%) and while these patients are eligible to receive targeted endocrine 
therapies, up to 30% of patients will experience a recurrence. Others will fail to respond to front-line 
endocrine therapies, while more patients will become resistant to endocrine therapies over time. We 
aimed to understand how fibroblasts play a role in the progression from hormone-dependent to 
hormone-independent growth. The cell culture data was translated to patient samples using 
bioinformatics approaches and label-free chemical imaging. Further, we define one aspect of the 
interaction between breast cancer cells and fibroblasts through identifying secreted proteins that are 
involved in the stromal-epithelial communication. The 43-protein signature can be used to classify 
breast cancer patients based on their corresponding gene expression profile, and we found that the 
signature is significantly upregulated in patients with more invasive disease. 
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In order to continue translating our results from cell culture to patient samples, we describe the 
application of label-free Fourier transform infrared spectroscopic imaging to monitoring breast cancer 
cell phenotypes. Chapter four details how biological changes can be spatially resolved in heterogeneous 
samples while in chapter five an approach to determine estrogen receptor presence and function in cell 
culture samples and patient biopsies is discussed. We show how FT-IR imaging can be used to define 
label-free spectroscopic signatures that are consistent between cell culture and patients, and explore 
how this approach may be used in the future to add additional information to current pathology 
practice. 
 We have developed a method to both understand the molecular mechanisms involved in how 
the microenvironment regulates early breast cancer phenotypes and to detect altered cellular 
phenotypes using label-free FT-IR imaging. We aim to apply this systems pathology approach to the 
development of novel diagnostic and prognostic signatures for determining the trajectory of cancer 
progression at very early stages. 
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CHAPTER ONE: INTRODUCTION 
 
Motivation and Impact 
 
We recently passed the 40th year in the war against cancer. While breast cancer incidence and 
deaths have declined over the last decade in the United States, breast cancer remains the most common 
cancer site among women and the second leading cause of cancer-related death (1). Disease is 
increasingly being detected early in some populations, while screening fails to identify the most lethal 
subtypes of breast cancer that are more likely to be found in certain groups (African Americans, 
Hispanics, and women under the age of 50). In this emerging era of big data, novel diagnostic and 
prognostic markers are being evaluated for their efficacy in improving understanding of disease 
progression and providing opportunities for therapeutic intervention. Recently, the National Cancer 
Institute assembled a list of 24 provocative questions from the research community to focus the efforts 
of researchers on those ideas that have the greatest potential impact on patients. These questions were 
divided into four themes, one of which is tumor detection, diagnosis, and prognosis. The questions in 
this theme are (2): 
 
1. Can we determine why some tumors evolve to aggressive malignancy after years of 
indolence? 
2. How can the physical properties of tumors, such as a cell’s electrical, optical, or 
mechanical properties, be used to provide earlier or more reliable cancer detection, 
diagnosis, prognosis, or monitoring of drug response or tumor recurrence? 
3. Are there definable properties of pre-malignant or other non-invasive lesions that 
predict the likelihood of progression to metastatic disease? 
4. What molecular events establish tumor dormancy after treatment and what leads to 
recurrence? 
 
These questions summarize the motivation for our efforts. In this work, information is integrated from 
both molecular and optical approaches to investigate the progression of breast cancer from confined to 
invasive disease. Specifically, the ways in which fibroblasts, the predominant cell type found in the 
tumor microenvironment of the breast, alter breast cancer phenotypes is investigated. Further, label-
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free spectroscopic signatures of cancerous phenotypes are described. We define this as a systems 
pathology approach for understanding cancer progression, in an effort to develop novel diagnostic and 
prognostic tools based on an understanding of the mechanism coupled with physical properties of 
cancer cells and tissues. 
 
Breast cancer prevalence and current clinical challenges 
 
Breast cancer is the second most common cancer site in women and carries an estimated 1 in 8 
lifetime risk. It is estimated that 234,580 new cases of invasive breast cancer will be diagnosed and 
40,030 men and women will die from the disease in the United States in 2013 (1). Further, while overall 
incidence of confined tumors has stabilized over the last decade, diagnosis of ductal carcinoma in situ 
(DCIS) is increasing in younger women, with approximately 57,650 cases diagnosed in 2011 (1). Although 
the overall five-year survival rate is 89% across all stages of disease, the relative survival rates are 99% 
for localized disease, 84% for regional disease (in which one or more lymph nodes is affected), and 23% 
for distant-stage disease (3). While cancer is increasingly being detected and treated at an early stage, 
there is a population of patients who do not respond to first-line therapies, and when their cancer 
recurs, it is often more invasive and resistant to therapy (4). 
 
Molecular targeted therapies have shown clinical promise. The majority of breast cancers 
diagnosed are estrogen receptor positive (ER+) (5). These tumors are associated with favorable 
prognosis because the presence of estrogen receptor α (ERα) and/or Progesterone receptor (PR) 
predicts a good response to endocrine therapy such as selective estrogen receptor modulators (SERMs) 
and aromatase inhibitors (AIs). However, because patients with the equivalent tumor stage and receptor 
status can have different responses to the same therapy (6), molecular subtyping by gene expression 
signatures in clinical samples and human breast cancer cell lines (7,8) has recently emerged as an 
exciting approach for determining personalized therapies. One clinical success story, Trastuzumab 
(Herceptin) is a monoclonal antibody that targets the HER-2/neu protein that is upregulated in 15-30% 
of breast tumors. Although molecular subtyping may improve targeted therapies, it is unclear what 
causes tumors to recur after treatments. Up to 30% of patients placed on endocrine therapy will 
experience a recurrence (9). It would be advantageous to understand molecular interactions at the time 
of first biopsy in order to guide breast cancer treatment. 
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The microenvironment is a regulator of cancer phenotypes 
 
Cells are very sensitive to chemical and mechanical changes in their microenvironment, which 
can provide cues for developmental and other intracellular programs (10,11). Culturing epithelial cells in 
three-dimensional (3D) matrices leads to differential expression and localization of cell receptors (12). 
Gene expression profiling of breast cancer cell lines grown in 3D shows that this type of culture 
condition is more relevant for translating results to clinical samples (13). Similarly, tumor cells interact 
with the local microenvironment in what is now known to be a key regulatory step for cancer 
progression. Seminal work in this field has shown that cancerous phenotypes can be stimulated (14-16) 
or suppressed (17-19) simply by altering the tumor microenvironment. The tumor microenvironment, or 
stroma, in ductal carcinoma consists of extracellular matrix proteins (primarily fibrillar collagen) and a 
variety of cells including fibroblasts and macrophages. Cancer-activated stroma, characterized by the 
presence of cancer-activated fibroblasts (CAFs) that express α-smooth muscle (α-SMA) protein, is 
associated with poor prognosis in breast cancer (20-22). Although the heterotypic interactions between 
fibroblasts, extracellular matrix, and cancerous epithelial cells are being studied by our group and 
others, it is unclear how the sum of these interactions determines the tumor outcome. 
 
While many stromal cell types have been implicated in disrupting tissue homeostasis and tumor 
progression, including immune cells, supporting cells, cells of the vasculature, and mesenchymal stem 
cells, we focused on the role of fibroblasts in particular. Fibroblasts maintain normal tissue homeostasis 
in many organs (23-24). Because of their important role in regulating breast epithelium during 
differentiation (25), we hypothesized that fibroblasts influence epithelial proliferation and invasion 
during the early stages of cancer progression. Specifically, the paracrine signaling that occurs between 
epithelial cells and fibroblasts was investigated, as this has the potential to provide novel therapeutic 
targets as well as an understanding of the basic mechanisms that drive tumor progression from confined 
to invasive disease. 
 
Many three-dimensional culture models have been described to study breast cancer (26-30). Co-
cultures have also been reported to study the interaction of cancer cells with fibroblasts (31,32), cancer-
associated fibroblasts (33-35), macrophages (36), adipocytes (37), and normal epithelial cells (38). We 
combined a 3D model with both epithelial and stromal components in which the cells were grown in a 
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physiologically-representative context. Epithelial cells were grown in a recombinant basement 
membrane (Matrigel) model to support normal epithelial architecture (30). Nontumorigenic and normal 
epithelial cells formed growth-arrested acinar structures with established lumens while cancer cells 
formed spheroid structures without lumens. Fibroblasts were grown dispersed within type I collagen 
gels. These methods and the characterization of this 3D model are described in Chapter 2.  
 
Defining predictive signatures of breast cancer progression  
 
 Many signatures of breast cancer have been reported that correlate expression levels of genes, 
proteins, or microRNAs in cells and tissues to patient outcome (39-44). However, only a few of these 
signatures have led to clinical utility, most notably the van’t Veer 70-gene prognostic signature that led 
to the MammaPrint test (45,46), the Oncotype Dx system (47,48), and the PAM50 score (49-51). 
Although it is established that tumors are heterogeneous, the majority of molecular signatures defined 
in the literature are based on approaches that take the average expression of hundreds to thousands of 
cells. Hence, the true molecular portrait of the tumor is not described because contributions of various 
phenotypes are averaged. Further, recent reports have shown that the gene expression in the tumor 
stroma also has prognostic significance (43,44). These findings suggest that an approach that combines 
the spatial localization of immunohistochemistry, the computational approaches of gene signature 
classification, and the molecular mechanistic understanding of in vitro experiments would be an ideal 
diagnostic/prognostic strategy. We explore the use of such a strategy here, using three-dimensional 
models of breast cancer progression and Fourier transform infrared (FT-IR) spectroscopic imaging with 
an emphasis on the study of the behavior of ER+ cancers. 
 
Fourier transform infrared spectroscopic imaging can be used to define label-free chemical signatures of 
disease progression 
 
We employed an emerging technology to translate results from cell culture to patient tissue 
specimens. Fourier transform infrared (FT-IR) spectroscopic imaging can be used to describe label-free 
molecular signatures of cellular transformation. FT-IR measures the absorption of energy by molecular 
bonds at characteristic wavelengths and can be used to quantify the relative amounts and distributions 
of chemical bonds present within a sample (52,53). Infrared radiation cannot be seen with the human 
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eye and consists of wavelengths between 0.7 and 300 µm. Wavelengths in the mid-infrared region, used 
for this work, are 2-14 µm (52). Many biomolecules of interest can be detected in this regime. 
 
We and others have correlated cellular transformations with spectroscopic signatures. Our 
previous work shows that the activation of fibroblasts to myofibroblasts after treatment with TGF-β or 
co-culture with cancer cells can be monitored using IR imaging (54,55). Our lab has also shown that 
melanoma progression can be characterized in an engineered model of skin by studying the stromal 
changes around the cancer cell (56). We have demonstrated that chemical imaging is a powerful tool for 
studying biological phenomena at the bench and that these results can be translated to human tissue. 
Through the development of computational algorithms, we are able to classify cell types in patient 
biopsy specimens based on their spectroscopic profiles. Importantly, the sample processing for IR 
imaging is minimal. Formalin fixed and paraffin embedded (FFPE) tissues can be used and no stains are 
required. FT-IR imaging may be easily worked in with the current clinical workflow, providing additional 
information to the pathologist about the tissue characteristics.  
 
A schematic of an FT-IR imaging instrument is shown in Figure 1.1 (57). Briefly, a heated filament 
infrared source is used and the energy is passed through a Michelson interferometer. This energy is 
broadband, consisting of all of the wavelengths to be measured. The energy is then directed through a 
microscope objective, where it interacts with the sample of interest. In a transmission measurement, 
the energy passes completely through both the sample and the substrate before it is detected. In a 
reflection measurement, as was used primarily in this work, the energy passes through the sample and 
is mostly reflected off of the substrate before passing through the sample again. The energy is detected 
with a liquid nitrogen-cooled mercury cadmium telluride (MCT) detector. Interaction with the sample 
has altered the characteristics of the energy, and this can be analyzed with a Fourier transform, which 
converts the absorption as a function of the position of the mirror in the interferometer to the 
absorption of each wavelength. Because molecular bonds vibrate at characteristic wavelengths, 
information about the quality of the sample can be assessed. In FT-IR imaging, the sample is placed on 
an x-y-z microscope stage and the absorption at each wavelength is measured for each pixel. The pixel 
size for both transmission and reflection modes is 6.25 m x 6.25 m, sufficient for looking at individual 
cells. Another mode used in this work is attenuated total reflectance (ATR) FT-IR imaging. This mode 
places a crystal made of a high refractive index material, in this case Germanium (refractive index = 4), 
directly in contact with the sample. The crystal acts as a solid immersion lens. This results in a four-fold 
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improvement of spatial resolution, reducing the pixel size to 1.56 x 1.56 m. The signal-to-noise ratio is 
also improved because all of the light from the sample is directed back into the instrument and there 
are less optical aberrations due to scattering (58). The limitations of this mode are that contact from the 
crystal can be damaging to the sample and the total scanning area is limited by the size of the crystal 
(usually 500 m x 500 m to 1 mm x 1 mm).   
 
With either mode, the resulting dataset is three-dimensional. Each pixel in the image represents 
the chemical spectrum of the corresponding sample area. A characteristic FT-IR spectrum is shown in 
Figure 1.2 and an example of an image is shown in Figure 1.3. The image is the distribution of the 
absorbance values for a particular peak. The peak shown in Figure 1.3 is 2960 cm-1, which corresponds 
to the asymmetric vibrational mode of CH3 stretching, associated with phospholipids, fatty acids, and 
triglycerides, and can be used as a marker of metabolism (56,59). Other peak assignments and their 
corresponding biomolecule signatures are described in Table 1.1. Using FT-IR imaging, the chemical 
nature of complex samples can be described with a spatial resolution that can identify subcellular 
changes. The investigation of FT-IR imaging as a tool to describe hormone response in cells and tissues is 
described in Chapters 3 and 4. We also correlate spectroscopic signatures with the expression, 
localization, and function of the ER protein, a significant prognostic marker for breast cancer in 
Chapter 5. 
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Figure 1.1: Schematic of FT-IR imaging instrument used for this work. Used with permission (57). 
 
 
 
Figure 1.2: Characteristic FT-IR absorbance spectrum with labeled peaks of interest. 
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Table 1.1: Bond assignments for peaks commonly used in biological studies. Adapted from (56). 
Wavenumber (cm-1) Bond Assignment Biomolecule Assignment Reference 
3550-3000 -OH Water (60,61) 
2960 Asymmetric CH3 
stretching 
Fatty acid (Saturated) (61-63)  
2930 Asymmetric CH2 
stretching 
Fatty acid (Saturated) (61-63)  
2870 Symmetric CH3 
stretching 
Fatty acid (61-63) 
2850 Symmetric CH2 
stretching 
Fatty acid (Saturated) (61-63) 
1656 Amide I (80% C-O 
stretching) 
Protein (61) 
1550 Amide II (60% N-H 
bending, 40% C-N 
stretching) 
Protein (61) 
1400 C-O stretch of COO- Fatty acid (61) 
1284, 1240, 1203 Amide III (40% C-N 
stretching, 30% N-H 
bending, 20% methyl 
stretching) 
Collagen (64) 
1224 Asymmetric PO2
- 
stretching 
nucleic acids, phospholipids (61-63) 
1170 C-O asymmetric 
stretching 
esters (61) 
1080 Symmetric PO2
- 
stretching 
nucleic acids, phospholipids (61-63) 
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Figure 1.3: Image of a 1.5 mm breast tissue core at 2960 cm
-1
, showing distribution of -CH3 bonds, corresponding to fatty 
acids. 
 
Summary 
We were motivated to determine which factors determine the course of early breast cancer 
progression and hypothesized that interactions with the microenvironment, and in particular fibroblasts, 
are key regulators of cancerous phenotypes. Our model of tumor growth is based on a constantly 
evolving landscape that involves factors at many levels of regulation, length scales, and time scales. 
Here, we discuss the approaches and tools that can be used to study early fibroblast-tumor interactions. 
In particular, we describe how the microenvironment can alter breast cancer cell phenotypes from a 
systems pathology perspective – integrating molecular profiling with chemical imaging from cells to 
tissues.  
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CHAPTER TWO: THREE-DIMENSIONAL CELL CULTURE MODELS FOR STUDYING THE EFFECT OF 
FIBROBLASTS ON BREAST CANCER PHENOTYPES 
 
Abstract 
Approximately 232,340 women will be newly diagnosed with breast cancer in 2013. With 
advances in screening and diagnosis, confined disease is being detected earlier. Cancer management 
strategies would benefit greatly from an improved understanding of early molecular events that control 
cancer progression. In confined breast carcinomas, these events are driven by the reciprocal interaction 
between the cancerous epithelium and its microenvironment, the stroma. Sophisticated cell culture 
techniques have emerged as a way to study this interaction. Here, we report a novel three-dimensional 
co-culture model that combines the MCF10A mammary acinar model with a stroma simulated by 
primary human fibroblasts embedded in a type I collagen matrix. This layered model enabled the growth 
of two cell types in a complex environment while allowing for the easy mechanical separation of the two 
populations. The effects of propagating signals through the environment were studied by using a two-
stage sandwich co-culture model. By first co-culturing the stroma with MCF-7 tumorigenic breast 
epithelial cells and allowing the fibroblasts to become activated, a cancerous molecular signature 
propagates through the stroma to affect the normal adjacent epithelium. The changes in the normal 
epithelium were assessed using proliferation and migration assays, morphology as determined through 
hematoxylin & eosin staining, quantitative real-time PCR for gene expression, and Fourier Transform 
Infrared (FT-IR) spectroscopic imaging. Label-free FT-IR can measure global chemical changes within a 
sample and can lead to better understanding of the early molecular events occurring between a tumor 
and its microenvironment.  
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Introduction 
Carcinomas, including those arising from the epithelium of skin, breast, prostate, and colon, are 
the most common types of cancer and their worldwide incidence is increasing (1). While the global 
genomic and proteomic landscapes are being mapped, the dynamics of the etiology of most carcinomas 
are still not defined. Attention has shifted to so-called ‘targetable’ mutations, but the systematic study 
of both targets and potential therapies continues to be done with animal models and monolayer culture 
based approaches. 
 
The importance of developing more physiological systems for studying cancer has been 
appreciated over the last decade (2-5). It is now understood that cells are extremely sensitive to their 
mechanical and chemical environments, both locally and globally (6-9). Both normal and cancer cells 
have different gene expression signatures when grown in three-dimensional (3D) culture compared to 
growth on tissue culture plastic. It has been shown that the genomic profile of breast cancer cells grown 
in a 3D matrix resembles that of human disease states (4), while the profile of cells grown in monolayer 
culture does not. Recently, advanced 3D culture models for studying breast cancer have been developed 
in which the normal breast epithelial architecture is maintained (2,10). These models can be used to 
study genetic influences on cancer progression (11-12) and can also be used to test novel therapeutic 
agents (13-14). 
 
While consideration of the mechanical and chemical environment of breast cancer cells is 
important for relating in vitro studies to human disease, the tumor microenvironment has also been 
implicated in the progression of cancer and resistance to therapies (15-17). The tumor 
microenvironment is a complex milieu of mesenchymal and myeloid derived cells, extracellular matrix 
proteins, and chemical signals (Figure 2.1). Many cell types have been identified as potential drivers of 
tumor progression including macrophages (18), adipocytes (19), and fibroblasts (20). Co-culture models 
are used to study the interaction between tumor cells and other cells present in the environment. In the 
past, the cells are grown in two-dimensions either mixed together or separated by a membrane that 
allows soluble factors to be exchanged between the two cell types. More recently, microfluidic co-
cultures have been developed that allow for the study of interaction dynamics (21). Although cancer 
cells are known to behave differently in 3D culture, there are few co-culture studies that combine 3D 
culture conditions with multiple cell types. Those that have been developed are limited by the fact that 
the cells are mixed together and must be separated before molecular analyses of single cell type 
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profiles. Studies to determine gene expression are extremely sensitive to the presence of other cells and 
the genetic changes determined with these methods will always be an average of the contributions of 
both cell types. Separation of mixed populations of cells is challenging due to the lack of robust cell 
surface markers for certain tumor cells, for example cancer stem cells (22). Thus, we were motivated to 
develop a three-dimensional co-culture environment in which the cells could be grown together for a 
prescribed amount of time before separating them without the use of antibody-dependent bead-based 
approaches.  
 
Figure 2.1: The microenvironment milieu. Fibroblasts are the first stromal cells to contact signals from the primary tumor. 
 
While many cells have been implicated in affecting cancer cell phenotypes, we focused on 
fibroblast-epithelial interactions. When fibroblasts are co-cultured with breast cancer cells, they 
undergo a transformation and become more myofibroblast-like; this is characterized by the expression 
of α-smooth muscle actin protein (α-SMA). These cancer-activated fibroblasts (CAFs) are suggested to 
promote breast cancer progression (23). While the interaction between breast cancer cells and 
fibroblasts is well characterized in both cells (24-26) and tissues (27), how the presence of activated 
fibroblasts affects nearby normal epithelium is still unclear. We aimed to develop a model that could be 
used to study the propagation of cancerous molecular signatures from the tumor to nearby normal 
epithelium via the stroma, and in particular via fibroblast activation. 
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For this study, we developed a layered co-culture model in which breast cancer cells and 
primary fibroblasts were embedded within a type I collagen hydrogel. The layered model allowed for the 
communication between the two cell types via soluble factors in a more physiologically realistic system. 
After co-culture, the layers were peeled apart with forceps; each layer could be separately digested to 
isolate RNA from the individual cell types. To identify whether cancerous molecular signatures were 
propagated via the stroma, the layered model was used in a two-stage co-culture. Primary fibroblasts 
were first co-cultured with MCF-7 breast cancer cells in the layered model and, upon activation, that 
layer was peeled off and subsequently co-cultured with nontumorigenic MCF10A breast epithelial cells 
that were grown in 3D as growth-arrested acini. Phenotypes of cancerous transformation were 
monitored in MCF10A cells, including increased proliferation and increased migration, as well as 
expression of genes known to be altered in tumors. 
 
While bulk measurements, including cell-based assays and gene expression profiling, are the 
gold-standard in determining cancerous phenotypes in vitro, it is known that cancer cells are comprised 
of heterogeneous populations with widely varied phenotypes (28-29). In order to address cellular 
heterogeneity, as well as to understand the dynamic and reciprocal interactions between cell types, we 
used Fourier transform infrared (FT-IR) spectroscopic imaging to monitor bio-molecular changes in our 
cell culture samples. This label-free imaging method measures the characteristic absorption of energy by 
molecular bonds within a sample, and this can be used to determine spectroscopic signatures of cellular 
transformations in heterogeneous samples (30). By combining a novel 3D cell co-culture system with 
label-free chemical imaging, we aimed to understand the dynamic and reciprocal interactions between 
fibroblasts, breast cancer cells, and normal breast epithelial cells and how this interaction influences 
cancer progression. 
 
Results 
 
Development and Validation 
We were motivated to develop a three-dimensional cell co-culture model in which the cells 
could be grown together and separated easily. We came up with a layered model concept, referred to 
hereafter as the ‘Sandwich,’ where cells were embedded within hydrogels that were prepared 
sequentially such that a natural interface formed between the layers. This interface allows for the easy 
19 
 
separation of individual cell types because they are confined within the gel layer. Our other 
specifications for the model are outlined in Figure 2.2. Perhaps most importantly, the collagen gels are 
polymerized slowly by pre-incubating at 4°C for one hour prior to polymerization for one hour at 37°C. 
This controls the collagen fiber alignment and size as the hydrogel forms without any damage to the 
cells that are embedded within (31). These parameters are important to consider when culturing 
primary fibroblasts, as these cells are extremely sensitive to both local and global mechanical forces. 
 
Figure 2.2: Design considerations for 3D co-culture model. 
  
The cell interaction studied first was that between a widely-used breast cancer cell line, MCF-7, 
and primary normal dermal fibroblasts (NDF). Dermal fibroblasts were chosen for this initial study 
because mammary fibroblasts were not commercially available at the time, and NDF do not express high 
basal levels of α-SMA, the most widely used marker of the fibroblast-myofibroblast differentiation and 
cancer-activated fibroblasts (CAFs) (32). These cells had been used previously by our group and the 
dynamics of the interaction were characterized using immunofluorescence and FT-IR spectroscopic 
imaging (25-26). MCF-7 cells were able to activate NDF in the layered sandwich model after 12 hours of 
co-culture (Figure 2.3). As a positive control, NDF were treated with 1.5 ng/mL TGF-β1, a potent 
stimulator of the fibroblast-myofibroblast activation (33). 
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20 
 
 
Figure 2.3: 3D Fibroblast activation by 12h treatment with TGF-β1 or 12h co-culture with MCF-7. Scale bar represents 50 µm. 
  
The primary design consideration of the co-culture model was to ensure that there was no cell 
migration between the layers. This enables the facile separation of cell-containing layers by forceps, 
rather than separating the cells using magnetic bead pull-down or fluorescence assisted cell sorting 
(FACS). Although MCF-7 are not highly invasive in culture compared to other tumorigenic breast cancer 
cells (34), we wished to determine whether the cells were migrating between the layers in the sandwich 
model. A two-layered model was created in which MCF-7 and NDF were grown in separate layers. 
Samples were fixed at 6h, 12h, 24h, 48h, 96h, and 1 week, paraffin embedded, sectioned, and stained 
for the epithelial marker cytokeratin or mesenchymal marker vimentin. While the MCF-7 layers showed 
positive staining for cytokeratin, they were negative for vimentin staining, indicating the fibroblasts had 
not migrated into this layer. Conversely, the NDF layers showed positive staining for vimentin but were 
negative for cytokeratin, indicating that the MCF-7 also had not invaded (Figure 2.4).  
α-SMA
DAPI
negative control + TGF-β1 + MCF-7 co-culture
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Figure 2.4: Absence of cellular cross-migration was confirmed through immunohistochemical staining of individual cell layers 
for epithelial marker cytokeratin and mesenchymal marker vimentin. 
 
A two-stage co-culture model 
 After the sandwich culture was validated, we wanted to use the model to determine how 
cancerous signatures were propagated through the stroma, and in particular via activation of fibroblasts. 
A two-stage co-culture was developed in which NDF were first grown with MCF-7 and then, upon 
activation, co-cultured with MCF10A grown as growth-arrested acini. The schematic for setting up the 
experiment is depicted in Figure 2.5. MCF10A, a nontumorigenic breast epithelial line, has been widely 
used to understand the molecular drivers of breast tumors because it forms structures that have 
characteristically normal cellular architecture when grown in recombinant basement membrane gels (2). 
The cells become growth arrested spheroids after 8-10 days of culture and form normal cell-cell 
junctions with apical-basal polarity. Fibroblasts were activated after 12h co-culture with MCF-7 (Figure 
2.3) prior to co-culture with MCF10A acini. After 6, 12, 24, 36, 48, 72, and 168h, the MCF10A were 
analyzed for cancerous cellular phenotypes including increased proliferation, increased invasive 
potential, and gross differences in cytoarchitecture and morphology. As a control, naïve NDF (cells not 
previously co-cultured) were also grown with MCF10A acini for the same lengths of time. 
 
MCF-7 (Cytokeratin) NDF (Vimentin)
Vimentin stain (-)
in NDF layer
Cytokeratin stain (-)
in NDF layer
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Figure 2.5: Setting up the two-stage co-culture model. 
 
MCF10A undergo morphological changes after co-culture with activated fibroblasts 
 MCF10A form stable, growth-arrested acinar structures with clear lumens after 8 days in culture 
(2).  Therefore, we used disruption of the acinar structure as a preliminary test of the capacity of 
activated fibroblasts to induce oncogenic changes in these previously nontumorigenic cells. Samples 
were sectioned and subsequently stained using hematoxylin and eosin (H&E), a commonly-used 
histologic stain that is used to distinguish nuclei (stained purple) from other eosinophilic structures 
(stained red or pink). While a section through MCF10A cells grown alone reveals a single layer of cells 
surrounding a clear, central lumen, co-culture induces morphological changes in the acinar structure. 
After co-culture with activated fibroblasts (referred to hereafter as NDF+), cells were seen invading into 
the luminal space (Figure 2.6). However, after 24h of co-culture with NDF+ the acinar structure is 
completely lost, as cells continue to proliferate into the luminal space. This is not seen in all acini on the 
slide, suggesting there may be heterogeneity in the MCF10A response to fibroblast co-culture. 
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Figure 2.6: Hematoxylin and eosin stained MCF10A acini after co-culture. After only 6 hours of co-culture with activated NDF, 
there is invasion into the luminal space. After 24h, the cells are proliferating into the luminal space and the architecture is 
highly disrupted. 
 
MCF10A become more proliferative after co-culture with activated fibroblasts 
 Three of the ten “hallmarks of cancer” are sustaining proliferative signaling, evading growth 
suppressors, and resisting cell death (35). It was important to assess whether MCF10A were in fact more 
proliferative after co-culture with NDF+. First, a proliferation assay was done in which cells were 
digested out of the basement membrane matrix and plated in monolayer culture. After 24, 48, or 72h, 
cells were trypsinized and counted (Figure 2.7). It appears that after 48h co-culture with NDF+, MCF10A 
have been transformed such that they proliferate at an increased rate even when the stimulus is 
removed. However, there is a large degree of error associated with this experiment. This is not an 
accurate representation of proliferation, as the cells may be responding to the changed environment 
rather than a fibroblast-induced transformation. Therefore, proliferative potential was measured by 
staining MCF10A acini in situ for the presence of Ki67 protein (Figure 2.8), a marker of entry into the 
active phase of cell cycle (36). In growth-arrested MCF10A cells, this protein is absent from the nucleus 
(2).   
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Figure 2.7: Proliferation assay shows differences between MCF10A with and without co-culture. 
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Figure 2.8: Phase-contrast (top) and immunofluorescence imaging of MCF10A acini. Upon co-culture with activated 
fibroblasts, previously growth-arrested cells begin to proliferate, expressing Ki67. Scale bar represents 50 µm. 
 
MCF10A become more invasive after co-culture with activated fibroblasts 
 Although proliferation is a hallmark of tumorigenesis, confined carcinomas are rarely lethal. 
Rather, the mortality associated with cancer is the result of metastatic disease, after tumor cells invade 
the basement membrane and enter the bloodstream. Therefore, we aimed to measure the invasive 
potential of MCF10A cells after co-culture with normal or activated fibroblasts. We hypothesized that 
activated fibroblasts would transform the MCF10A such that they were more invasive in a standard 
wound healing assay. After co-culture with NDF or NDF+, MCF10A acini were digested from Matrigel and 
plated in monolayer culture. After a confluent monolayer formed, the plate was scratched and then 
images were taken every 6 hours for a total of 48 hours (Figure 2.9). While cells co-cultured with NDF+ 
for 6 hours were significantly more migratory than naïve MCF10A, co-culture with non-activated 
fibroblasts also induced a mild migratory phenotype. Interestingly, this trend was lost when the 
fibroblasts had been co-cultured for longer than 6 hours. This suggests either transience in the activated 
state of fibroblasts or in the interaction between fibroblasts and MCF10A cells. 
Phase-
contrast
MCF10A acini 
+ 24h NDF+
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Figure 2.9: Migration of MCF10A with and without co-culture as a fraction of wound closure. MCF10A are significantly more 
invasive after co-culture with NDF+ for 6 hours. Interestingly, this property is lost at a sustained co-culture time. 
 
Co-culture with fibroblasts changes the gene expression of key genes in MCF10A acini 
 Finally, we wished to determine what impact fibroblast co-culture has on the gene expression of 
MCF10A acini. Several key genes previously indicated in fibroblast-epithelial interactions were 
measured. IL-6 is known to be involved in the paracrine signaling between cancer cells and fibroblasts, 
and has been implicated in paracrine and autocrine networks that promote invasive phenotypes in 
prostate cancer (37). After co-culture with NDF+, IL-6 was upregulated compared to naïve MCF10A 
(Figure 2.10). Conversely, IL-6 is downregulated in MCF10A after co-culture with NDF. The paracrine 
signaling axis of NDF/MCF10A differs from that of NDF+/MCF10A, and is dynamic over time. In three 
independent replicates, the level of IL-6 mRNA in MCF10A after co-culture with NDF+ was highly 
variable, depicted by the large error bars in these samples. Because these are bulk measurements that 
take into account the mRNA levels of thousands of cells, this error could represent the heterogeneity 
induced in MCF10A acini upon co-culture with NDF+. After one week of co-culture, there may still be 
cells that are growth-arrested or undergoing apoptosis, which would reduce the overall mRNA 
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expression of IL-6 because these cells are not actively undergoing transcription of this gene. A more 
appropriate assay would be to check the IL-6 protein level using ELISA or western blot, to determine 
how much is being produced. 
 
 
Figure 2.10: Relative mRNA expression of IL-6. Co-culture with NDF+ increases IL-6 expression and this trend is sustained at 
longer timepoints. Significance of p < 0.05 is marked by *. 
 
 Next, E-cadherin gene expression was measured (Figure 2.11). Loss of this protein, important for 
maintaining normal epithelial cell-cell junctions, is a hallmark of the epithelial-to-mesenchymal 
transition (EMT) and is associated with invasive phenotypes and metastatic disease (38-40). Fibroblasts 
have been previously shown to induce an EMT in breast cancer cells and this will be discussed more 
thoroughly in Chapter 3 (41). When NDF or NDF+ were co-cultured with MCF10A acini, mRNA levels of E-
cadherin were quickly downregulated, after only 6 hours of co-culture. This early response was lost, 
however, after longer periods of co-culture. Again, this could indicate a transient phenotype in the 
fibroblast activation or in the response of MCF10A to stimuli secreted by NDF or NDF+. Interestingly, 
both normal and cancer-activated fibroblasts can induce this change. 
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Figure 2.11: Relative mRNA level of E-cadherin, a marker of normal epithelial cell-cell junctions. E-cadherin is downregulated 
in both conditions but the levels are restored after 1 week of co-culture. There were no significant differences between 
conditions. 
 
Chemical imaging can be used to measure cellular transformations in MCF10A cells after co-culture 
 Finally, we employed vibrational spectroscopy to determine global chemical changes occurring 
across MCF10A acini after co-culture with NDF and NDF+. We have used FT-IR spectroscopic imaging 
previously to monitor the fibroblast activation process in 3D co-culture with MCF-7 cells (25). Here, we 
aimed to understand the effect activated fibroblasts have on the spectral signatures of normal breast 
epithelial cells. Acini were paraffin embedded and sectioned onto IR-reflective substrates. Attenuated 
total reflectance (ATR) mode was used in order to obtain a pixel size of 1.56 x 1.56 µm. With this mode, 
the acinar structure can be seen, although individual cells cannot be discriminated (Figure 2.12). 
Individual acini were analyzed and the spectra from each condition were averaged. The average spectra 
for the 24h timepoint is shown in Figure 2.13. There are apparent differences in the peak at 3300 cm-1, 
associated with the N-H bond of proteins, however this peak is not used in our analysis due to its large 
variability across samples from sample processing. This large peak is effectively masked out of our 
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analysis. There are two primary regions of interest on the IR spectrum for studying cell biology: the C-H 
stretching region (3000-2800 cm-1), containing peaks from CH2 and CH3 stretching, and the so-called 
fingerprint region (1750-950 cm-1). The C-H stretching region is associated with fatty acids, lipids, and 
general metabolism (42). Analysis of this region across the three samples displayed reveals striking 
differences between the three culture conditions (Figure 2.14). Co-culture with NDF for 24h induces a 
peak shift in all three peaks of the region. Co-culture with NDF+, however, reduces the absorbance at 
the 2956 cm-1 peak and a shift at the 2850 cm-1 peak. Importantly, the three co-culture conditions can be 
readily distinguished using FT-IR. In the fingerprint region, however, the peak most closely associated 
with the phosphate backbone of nucleic acids (1080 cm-1) is greatly increased upon co-culture with 
NDF+ (Figure 2.15). This corresponds to NDF+ acting as a stimulant for MCF10A proliferation after 24 
hours of co-culture. 
 
 
Figure 2.12: MCF10A acinus after 24h co-culture with NDF. Image is of the peak at 1540 cm
-1
, corresponding to Amide II (N-H 
(40-60%) and C-N stretching (18-40%)). Scale bar represents 50 µm. 
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Figure 2.13: There are spectroscopic differences in MCF10A after co-culture with NDF or NDF+. The largest difference is seen 
at the 1080 cm
-1
 peak, associated with nucleic acids. 
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Figure 2.14: Analysis of the C-H stretching region of the spectrum reveals peak shifts at three peaks associated with fatty 
acids and lipids after co-culture with NDF or NDF+. NDF appear to induce the largest changes in this region. 
 
Figure 2.15: The fingerprint region (1750-950 cm
-1
) reveals a number of changes, including a peak shift at Amide II and a large 
increase in the peak at 1080 cm
-1
, associated with nucleic acids, after co-culture with NDF+ but not NDF. 
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Discussion 
 We have developed a novel 3D co-culture model for studying the interactions between 
fibroblasts and epithelial cells during early breast cancer progression. While there are many 3D culture 
platforms for studying cell cross-talk (10, 21, 43), our model has a number of unique features. The 
model uses a layered system that is reproducible and is modular, allowing for multiple co-culture 
configurations within a single experiment. We used the model in a two-stage co-culture experiment, in 
which primary fibroblasts were activated through co-culture with MCF-7 cells; these were subsequently 
co-cultured with growth-arrested MCF10A acini. We used this system to understand how cancerous 
molecular signatures propagate through the stroma and affect nearby epithelium. MCF10A acini were 
analyzed for various cancerous phenotypes, including proliferation, migration, and altered gene 
expression, as well as analysis of spectroscopic signatures associated with proliferation and metabolism. 
 
 We found that cancer-activated fibroblasts are sufficient for inducing cancerous phenotypes in 
growth-arrested mammary acini. The morphology of acini after co-culture with NDF+ was consistent 
with re-entry into the cell cycle and proliferation into the luminal space, forming a tumor-like structure. 
Although this type of morphology has been induced by the activation of oncogenes in vitro (11-12), this 
is the first time this has been shown to be the result of aberrant signaling between fibroblasts and a 
model of normal breast epithelium. Further, the MCF10A are transformed such that even after they are 
removed from the 3D matrix and seeded back onto tissue culture plastic, they are more proliferative. 
Fibroblast-activated MCF10A were also significantly more migratory in a wound healing assay. While the 
phenotype is transient in 3D co-culture, a combination of aberrant cellular signaling and the mechanical 
stress from the tissue culture plastic transform nontumorigenic epithelial cells into cancer-like cells. To 
further test the tumorigenic potential of these activated MCF10A cells, an animal model should be used. 
 
Further evidence to support an MCF10A transformation was shown by measuring the 
expression of two genes associated with fibroblast-epithelial interactions in the tumor 
microenvironment. Co-culture with NDF+ induces IL-6 overexpression in MCF10A, which could indicate 
the beginnings of a paracrine signaling loop between transformed epithelial cells and other stromal 
cells. IL-6 secretion has been implicated in recruitment of inflammatory cells, which have been 
correlated with poor outcome in several cancer types (44-45). Further, high IL-6 serum levels detected in 
breast cancer patients is a prognostic indicator for poor prognosis (46-48). Our studies suggest that IL-6 
may be released by transformed epithelial cells upon contact with activated fibroblasts, serving as a 
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marker for tumor progression even after the primary tumor has been removed. IL-6 expression is also 
associated with an EMT phenotype, characterized by loss of E-cadherin (49). Gene expression analysis 
shows that while both NDF and NDF+ reduce the levels of E-cadherin in MCF10A, E-cadherin levels are 
recovered after 1 week. The transience of the EMT phenotype may further indicate that a second ‘hit’ is 
necessary for them to become cancerous, or it is possible that fibroblasts lose their activation state after 
many days in co-culture with MCF10A. An experiment in which fibroblasts are continually activated by 
MCF-7, or in which activated fibroblasts are added every day to an MCF10A co-culture would determine 
if the limiting step in driving EMT is the activation state of the fibroblasts or the plasticity of MCF10A 
cells. 
  
Although we hypothesized that co-culture with activated fibroblasts would alter MCF10A 
phenotypes, we found that normal fibroblasts can also induce some changes in normal epithelial cells. 
While normal fibroblasts have been indicated to be anti-proliferative to both breast cancer cells and 
normal epithelial cells in the literature (50), we show that MCF10A have a response to NDF within the 
first 6-12 hours of co-culture. This appears to be more transient than the effect of NDF+ on MCF10A, but 
it is worth noting. The phenotypic changes seen in MCF10A suggest that growing epithelial cells in either 
monolayer or 3D culture is very dissimilar to growing them in co-culture with fibroblasts, regardless of 
their activation state. These findings indicate that co-cultures should be used over monocultures in 
doing systematic analysis of factors that are implicated in driving tumor progression or in drug testing 
and development. 
 
Finally, FT-IR imaging was used to differentiate between the effect of NDF and NDF+ co-culture 
on the chemical changes induced in normal epithelial cells. We found that label-free FT-IR imaging can 
differentiate between the co-culture conditions. Absorbance in a peak associated with nucleic acids is 
significantly increased after co-culture with NDF+ compared to NDF, corresponding to the ability of 
activated fibroblasts to stimulate proliferation in normal epithelial cells. We used this system as a proof-
of-principle to show that label-free chemical imaging may be used to determine activation state in 
epithelial cells. We have previously shown that FT-IR can be used to characterize the dynamics of 
fibroblast activation in 3D culture (25), but this is the first time that the transition from normal to 
cancerous epithelium has been monitored using this technique. 
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In conclusion, we developed a novel three-dimensional co-culture model in which the cells could 
be grown together in a physiological context and then easily separated with no cell crossover. This 
layered system was used to study the role of fibroblasts in the propagation of cancerous signals from 
the primary tumor to nearby normal epithelium. Fibroblast-activated MCF10A showed the cancerous 
phenotypes of enhanced proliferation and migration as well as alterations in morphology and gene 
expression. We label this a transformation rather than a reaction because the MCF10A retained these 
hallmarks even after the fibroblast stimulus was removed and the environmental context was changed. 
An analysis of the chemical changes upon activation was also done, showing that activated MCF10A 
acini show chemical hallmarks of enhanced metabolism and proliferation. This system of an advanced 
cell culture model coupled with both molecular approaches and chemical imaging can reveal new 
insights into the dynamic and reciprocal interactions between cancer cells, fibroblasts, and normal 
epithelium.  
 
Materials and Methods 
Cell Culture 
MCF10A cells (a gift from Senthil Muthuswamy, Cold Spring Harbor Laboratory) were 
maintained in monolayer culture with DMEM/F12 (Invitrogen, Life Technologies, Carlsbad, California, 
USA) supplemented with 5% Horse Serum (Sigma-Aldrich, St. Louis, Missouri, USA), 20 ng/mL Epidermal 
growth factor (EGF, Peprotech, Rocky Hill, New Jersey, USA), 0.5 g/mL Hydrocortisone (Sigma-Aldrich), 
0.1 µg/ml Cholera Toxin (Sigma-Aldrich), 0.01 mg/ml Insulin (Sigma-Aldrich), and 1% Pen/Strep (Gibco, 
Life Technologies). Cells were grown as previously described (2). Normal adult primary dermal 
fibroblasts (NDF, ScienCell Research Laboratories, Carlsbad, California, USA) were maintained in 
complete fibroblast medium (FM, basal medium supplemented with 2% Fetal Bovine Serum (FBS), 1% 
Fibroblast Growth Supplement (FGS), and 1% Pen/Strep). Fibroblasts were used prior to passage 7 to 
ensure that the fibroblasts were not entering senescence. MCF-7 cells (ATCC, Manassas, Virginia, USA) 
were maintained in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS and 1% Pen/Strep.  
 
Preparation of 3D cultures 
 For the 3D layered sandwich model (‘Sandwich’), MCF-7 and HMF were embedded in a Type I 
collagen matrix, while MCF10A were grown as acinar structures in the Matrigel overlay culture. To 
prepare type I collagen gels with a final concentration of 2 mg/ml, pre-polymerized collagen (Type I 
collagen from rat tail tendon, BD Biosciences, San Jose, California, USA) was diluted 1:10 (v/v) with 10X 
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Phosphate-buffered saline (PBS). Cell suspension was added at a density of 1000 cells/µl for a total 
count of 300,000 cells/gel layer. 1N NaOH was added to the mix at a ratio of 0.023 µl NaOH/µl final 
volume in order to neutralize the acidic collagen and promote polymerization of the gel. The volume 
was brought up to the final volume (300 µl times the number of samples) in growth medium. After 
thorough pipetting with a P1000 micropipette, 300 µl of sample was dispensed into each well of a 48-
well plate. The plate was then refrigerated at 4°C for 1 hour followed by polymerization at 37°C in a 
humidified, 5% CO2 incubator for 45 minutes. After the gels were completely polymerized, 300 µl of 
fresh media was added to the top of the samples. Cells were equilibrated in the gels for 24 hours before 
setting up the experiment. This procedure was previously described in Holton et al (25). 
 
3D acinar cultures were prepared by spreading a thin layer of growth factor-reduced Matrigel 
(BD Biosciences) in 24 -well plates and seeding a low density of MCF10A on top (4,000 cells/well). The 
cells were seeded in 0.5 ml of Assay Medium (Growth medium with 5 ng/ml EGF instead of 20 ng/ml) 
containing 2.5% dissolved Matrigel. Media was replaced every fourth day.  
 
To prepare the Sandwich culture, NDF and MCF-7 gels were switched to low-serum (0.5% FBS) 
medium for 24 hours prior to co-culture. Then, NDF gels were layered on top of MCF-7 gels for 12 hours, 
allowing the NDF to become activated (NDF+), expressing α-SMA. As a control, some NDF samples were 
not co-cultured (labeled NDF). After the activation period, fibroblast gels were moved on top of MCF10A 
3D cultures that had been growing for 12 days. The MCF10A cultures at this stage were growth-arrested, 
with normal cell-cell junctions and clear lumens. NDF/NDF+ and MCF10A acini were co-cultured for 6h, 
12h, 24h, 72h, and 1 week prior to analysis. 
 
Proliferation Assay 
 To perform the proliferation assay, MCF10A were removed from 3D matrices at prescribed 
timepoints by adding ice cold PBS until the Matrigel dissolved. MCF10A were then rescued in complete 
growth medium, centrifuged at 1000 rpm for 3 minutes, after which the pellet was resuspended in 9 mL 
complete growth medium. This was divided between three 5 cm petri dishes. Cells were allowed to 
adhere to the plates and grow for 24h, 48h, and 72h. At these timepoints, cells were trypsinized, 
rescued, centrifuged, and resuspended in 1 mL medium. Cells were counted twice and the cell counts 
averaged to get the total cell count per plate. To compare growth curves, cell counts for 48h and 72h 
were normalized to the 24h timepoint.  
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Migration Assays 
 A wound healing assay was set up in the same way as the proliferation assay in that MCF10A 
cells were digested out of the 3D matrix and re-plated in 3 plates containing equal numbers of cells. 
After 24 hours for the cells to form confluent monolayers, a P200 pipet was dragged in a straight line 
along the center of the dish to create a wound. At 0h and 48h pictures were taken to show the rate at 
which cells migrated to close the wound. Images were analyzed in ImageJ by measuring the distance 
across the wound at 3 points on each sample, prepared in triplicate. A student’s two-tailed paired t-test 
was used to confirm significance of the migration assay data. 
   
Paraffin embedding 
For both immunohistochemistry and FT-IR imaging analysis, samples were fixed in freshly-
prepared 4% paraformaldehyde for 1 h, mounted in Histogel (Thermo Fisher Scientific Inc., Waltham, 
Massachusetts, USA), and then paraffin-embedded. For paraffin embedding, samples mounted in 
Histogel were dehydrated with serial ethanol washes (50%, 70%, 80%, 95%, 100%, 100% for 3 h each) 
followed by three 2 h clearing steps in xylenes, and finally four 1 h paraffin infiltration steps (ParaPlast 
Plus, Sigma-Aldrich). 
 
Hematoxylin and Eosin Staining 
 Hematoxylin and Eosin (H&E) staining was done on paraffin embedded 10 µm sections of 
MCF10A acini. In a glass staining dish, sections were deparaffinized and rehydrated with the following 
steps: 3 x 3 minutes in xylene, 3 x 3 minutes in 100% ethanol, 1 x 3 minutes in 95% ethanol, 1x 3 minutes 
in 80% ethanol, and 1 x 5 minutes in deionized water. Samples were then moved to hematoxylin (Sigma-
Aldrich) for 3 minutes. Excess dye was removed by rinsing briefly in deionized water. Stain was 
developed by placing samples in tap water for 5 minutes and the samples were destained by dipping 8-
12 times over 30 seconds in acid ethanol (70% ethanol containing 1% v/v HCl). The samples were further 
rinsed twice in tap water followed by a brief soak in deionized water. Excess water was blotted from the 
side holder before putting the samples in Eosin Y solution (Sigma-Aldrich) for 30 seconds. Samples were 
immediately moved to 95% ethanol for 5 minutes. Samples were dehydrated with the following steps: 2 
x 5 minutes in 95% ethanol, 3 x 5 minutes in 100% ethanol, 3 x 15 minutes in xylene. Slides were hard 
mounted in Clarion Mounting Medium (Sigma-Aldrich, discontinued and replaced by Organo Limonene). 
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Immunofluorescence 
 Immunofluorescence on MCF-7 and NDF gels was done on the entire gel in order to preserve the 
cell structure. To do immunofluorescence on MCF10A gels in situ, Matrigel was spread on the glass 
window of 35 mm round glass bottomed dishes (MatTek, Ashland, Massachusetts, USA) before cultures 
were prepared as previously described. After washing media off with PBS, samples were fixed in cold, 
freshly-prepared 4% paraformaldehyde for one hour. Then, excess paraformaldehyde was removed by 
washing samples three times in ice cold PBS. 0.15 M glycine (in PBS) was added for 10 minutes at room 
temperature to quench the paraformaldehyde. Wash steps of 3 x 5 minutes in PBS were performed in 
between each step of the process. Cell membranes were permeabilized with 0.2% Triton X-100 (in PBS) 
for 15 minutes at room temperature. Samples were blocked in 5% non-fat dry milk or 5% bovine serum 
albumin (Sigma-Aldrich) in PBS overnight at 4°C or 3 hours at room temperature. After the blocking step, 
3 x 5 minute washes were done in PBS containing 0.5% Tween-20 (PBS/T, Sigma-Aldrich).  Primary 
antibodies were diluted 1:100-1:500 in PBS/T containing 1% BSA and samples were incubated for 1 hour 
at room temperature. Secondary antibodies were diluted 1:200-1:1000 in PBS/T containing 1% BSA for 1 
hour at room temperature and were covered to prevent photobleaching. For nuclear staining, 300 nM 
DAPI (Invitrogen) in PBS/T was added for 10 minutes. After a final wash in PBS, samples were mounted 
with an anti-photobleaching agent (Vectashield H-100, Vector Laboratories, Burlingame, California, USA) 
and coverslipped before imaging. Primary antibodies used for this study were α-SMA (mouse anti-
human IgG2, 1:100, Dako, Carpinteria, California, USA), Ki67 (rabbit anti-human IgG, 1:100, Invitrogen), 
E-cadherin (mouse monoclonal IgG1, clone 1.B.54, 1:100, santa cruz biotechnology, Dallas, Texas, USA). 
Secondary antibodies used were Goat anti-mouse IgG-FITC (1:500, Abcam, Cambridge, England, UK), 
Donkey anti-Rabbit IgG-AF546 (1:200, Invitrogen). 
 
Immunohistochemistry 
For IHC, samples were sectioned at 10 μm onto poly-L-lysine coated slides (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA). Once dry, slides were deparaffinized (2 x 3 min xylene, 1 x 3 
min 1:1 xylene/100% ethanol, 2 x 3 min 100% ethanol, 1 x 3 min 95% ethanol, 1 x 3 min 70% ethanol, 1 x 
3 min 50% ethanol, cold tap water). Antigen retrieval was performed by boiling the samples in the 
microwave for 15 min in 10 mM sodium citrate buffer (pH 6.0). Slides were blocked in Tris-buffered 
saline (TBS) containing 10% FBS overnight at 4 °C. Primary antibody was added in TBS containing 1% BSA 
for one hour at room temperature. Monoclonal mouse anti-human Cytokeratin (Clone AE1/AE3, Dako), 
monoclonal mouse anti-Vimentin (Clone V9, Dako), and monoclonal mouse anti-αSMA (Clone 1A4, 
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Dako) antibodies were used at a dilution of 1:100 as per company specifications. The remainder of the 
protocol was performed as specified using a HRP/DAB detection kit (EXPOSE Mouse and Rabbit Specific 
HRP/DAB Detection IHC kit, Abcam, Cambridge, Massachusetts, USA).  
 
Quantitative Real-time PCR 
Total RNA was isolated from cells using TRIzol (Invitrogen). cDNA was prepared by reverse 
transcription with M-MuLV Reverse Transcriptase (New England Biolabs Inc, Ipswich, Massachusetts, 
USA). mRNA expression was measured using quantitative real-time PCR on a high-throughput ABI Prism 
7900HT real-time instrument (Applied Biosystems, Life Technologies, Carlsbad, California, USA) using 
SYBR Green PCR Master Mix (Applied Biosystems) as described previously (51). A paired, two-tailed 
student’s t-test was used to determine significance of changes compared with the control sample. 
Significance was set as p < 0.05. 
 
FT-IR imaging and data analysis 
 Paraffin-embedded samples were sectioned at 5 μm onto MirrIR IR-reflective glass slides (Kevley 
Technologies, Chesterland, Ohio, USA). Once dry, samples were deparaffinized in hexanes for 24 h and 
then air-dried completely before imaging. For FT-IR imaging, a PerkinElmer Spotlight 400 (PerkinElmer, 
Waltham, Massachusetts, USA) equipped with a thermal source and a raster-scanning linear array 
detector was used with a Germanium ATR imaging accessory. An NB medium apodization was applied, a 
1 cm s-1 mirror speed was used for acquisition, and zeropadding was not used. Background scans were 
taken at 8 cm-1 spectral resolution. 150 x 150 μm images were collected at 8 cm-1 spectral resolution 
with 16 scans per pixel and a 1.56 x 1.56 μm pixel size. Data were atmospheric and ATR corrected on the 
Spotlight, and further processing was done using ENVI-IDL (Exelis Visual Information Solutions, Boulder, 
Colorado, USA). A minimum noise fraction (MNF) algorithm was applied on all images (52) to reduce 
noise in the data. Two regions were imaged per sample, and samples were prepared in duplicate (for a 
total of 4 data sets per condition). 
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CHAPTER THREE: INTEGRATING MOLECULAR PROFILING AND CHEMICAL IMAGING TO UNDERSTAND 
HETEROTYPIC INTERACTIONS IN COMPLEX SAMPLES 
 
Abstract 
 
The tumor microenvironment is known to play a role in promoting cancer phenotypes and has 
been suggested as a potential therapeutic target. Its influence on therapeutic resistance and cancer 
relapse, however, is poorly understood. Here we investigate the interaction of mammary fibroblasts and 
estrogen receptor-positive breast cancer cells in a three-dimensional culture model and characterize the 
secreted protein factors involved in the cellular cross-talk. We show that fibroblasts induce an epithelial-
to-mesenchymal transition in the cancer cells, leading to hormone-independent growth, invasive 
phenotypes, and resistance to endocrine therapy. We use two technologies that may translate these 
conclusions from cell culture to patient samples: a secreted protein signature to stratify patient 
populations and label-free chemical imaging to study cellular hormone response. Our findings 
underscore the role of fibroblasts in promoting therapeutic resistance and highlight the use of novel 
approaches for the dynamic molecular subtyping of breast cancer. 
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Introduction 
 
More than 70% of breast cancers diagnosed in the US are estrogen receptor positive (ER+) (1, 2). 
ER+ tumors generally have more favorable prognoses compared to other subtypes and can be treated 
with targeted endocrine therapies, for example, with tamoxifen (3). Though most ER+ patients respond 
favorably to targeted therapy, up to 30% of treated cancers recur (3, 4). For patients with recurrent 
systemic disease, the five-year survival rate drops to 20%, with a median survival of 12-24 months (5). 
The factors underlying recurrence arising from endocrine resistance are not fully understood, but it is 
increasingly appreciated that the microenvironment of the tumor cells can play a critical role in 
impacting their behavior (6, 7).  
 
To gain a fundamental understanding of the molecular factors driving endocrine resistance and 
tumor recurrence, which cannot be fully elucidated in situ in humans, we have developed and employed 
cell culture models described herein. We hypothesized that normal fibroblasts serve at the frontline of 
heterotypic interactions experienced by cancer cells; not only are they the first line of defense 
presented by the body to dysplasia, they are also encountered in the microenvironment during every 
stage of disease progression. It is also now clear that three-dimensional (3D) cultures represent a more 
realistic model for tumors (8). While excellent 3D tumor models have been proposed (9, 10), 3D co-
cultures to study heterotypic interactions are less widely used (11, 12). Hence, we developed and 
employed a series of 3D co-culture systems to specifically and comprehensively investigate molecular 
epithelial-fibroblast interactions. In particular, we examined the impact of fibroblasts on tumor cell 
phenotypes and endocrine therapy responsiveness. We sought to obtain a molecular interaction 
signature (iSig) of differential epithelial-stromal interactions that characterizes the microenvironment-
influenced cancerous phenotype. The iSig is not only important for mechanistic insight into tumor 
progression but may provide an immediate route to characterizing the dynamics of tumor behavior. The 
efficacy of our dynamic iSig approach in predicting patient breast cancer outcome was compared to 
available gene expression profiling studies. 
 
In addition to examining cell phenotype using several molecular approaches, we incorporated a 
comprehensive profiling approach based on chemical imaging. As opposed to molecular imaging that 
measures only a few epitopes, emerging chemical imaging technologies use spectroscopy to provide 
functional and molecular information within cells and tissues without requiring staining or a priori 
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knowledge of molecular transformations. Here we employ Fourier Transform infrared (FT-IR) 
spectroscopic imaging (13) for rapid and label-free profiling of co-culture samples. By visualizing the 
inherent chemistry within a sample, cell activity changes and disease states in vitro (14, 15) and cell 
types within complex tissues (16-18) can be monitored. Although a number of studies have reported the 
development of high performance imaging, rapid data processing and classification algorithms, as well 
as applications to histologic analyses of tissues (19-22), few studies have related spectral data to 
underlying molecular transformations. To our knowledge, no studies have related the spectroscopic 
monitoring of tissues to underlying biological processes that drive tumor behavior – a concept that is 
developed here. 
 
In summary, we have monitored changes in gene expression and phenotypes arising from 
epithelial-fibroblast interactions and included FT-IR spectroscopy in a “bottom up” approach to 
understand the specific influence of stromal fibroblasts on breast cancer phenotypes. The first part of 
this study reports the step-wise validated development of the 3D co-culture model and the molecular 
and spatial information that is available from it. The second set of results focuses on molecular 
transformations and describes a secreted protein interaction signature that effectively predicts patient 
clinical outcomes. In the third set of results, we develop the chemical imaging signature of the 
underlying genomic states in endocrine responsive breast cancer. Together, these approaches provide a 
toolbox for understanding key aspects of breast cancer evolution and highlight a pivotal role for 
mammary fibroblasts in the tumor cell microenvironment in determining endocrine sensitivity or loss of 
response in breast cancer cells. 
 
Results 
 
3D culture systems were engineered to simulate epithelial-fibroblast interactions 
The four models shown schematically in Figure 3.1A and 3.1B allowed us to systematically 
simulate the microenvironmental influence on cancer cells as well as easily obtain material to analyze 
for the molecular signature of this interaction (Fig. 3.1C and 3.1D). MCF-7 breast cancer cells were 
grown in 3D on Matrigel, which is denoted hereon simply as MCF-7. The influence of fibroblasts was 
varied by geometry. A sandwich culture (MCF-7S) represents the compartmentalization of cancer cells 
and fibroblast-rich stroma, as may be observed in confined human tumors. Fibroblasts are embedded in 
a type I collagen matrix and grown in a separate layer.  Cells are able to communicate continuously via 
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molecular diffusion of soluble factors but do not migrate out of their respective layers (14). After a 
prescribed co-culture time, the layers are easily separated, and molecular analyses can be performed 
without any cell crossover. The mixed culture (MCF-7M) has cells mixed together before they are plated, 
allowing for cell-cell interactions arising from direct contact. Finally, to understand the transient 
influence of soluble factors, the conditioned medium (CM) culture consists of medium from MCF-7M 
added to the MCF-7 cells. This medium is also analyzed separately for soluble factors. In all situations, 
MCF-7 cells grew as spheroids. A combination of these models comprehensively interrogates the 
differential fibroblast-cancer cell interactions that influence cancer progression. 
  
Figure 3.1: Three-dimensional co-culture models and analytical approaches in this study.                                                               
We utilized several three-dimensional co-culture models to study the interactions between MCF-7 breast cancer cells and 
primary mammary fibroblasts. The MCF-7 were grown as spheroids in a Matrigel overlay culture. Fibroblasts were incorporated 
either in a direct-contact mixed culture (MCF-7
M
) or in a separate collagen layer in a sandwich culture (MCF-7
S
). To study the 
effects of paracrine signaling, conditioned medium (CM) studies were done in which CM was taken from the mixed culture and 
used to treat MCF-7 or normal mammary epithelial cells (HMEC) grown alone. The CM was also profiled using protein arrays. 
We used gene expression and phenotypic assays to study response to hormone and the expression of markers of EMT. This 
molecular profiling approach was correlated to label-free FT-IR spectroscopic imaging and also gene expression from patient 
samples. 
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Fibroblasts induce an EMT in cancer cells 
Because the epithelial-to-mesenchymal transition (EMT) in breast cancer cells has been 
associated with a loss of E2/ERα signaling and insensitivity to endocrine therapies (23, 24), we 
hypothesized that co-culture with HMF might induce an EMT phenotype. Epithelial cells from MCF-7S 
displayed increased levels of SNAIL (7-fold) and SLUG (25-fold) mRNA that were correlated with a 4-fold 
decrease of E-Cadherin mRNA (Fig. 3.2), all characteristic of the mesenchymal cell phenotype and 
hallmarks of EMT (25). These effects observed at 3 days were sustained at longer times, indicating that 
the induced EMT phenotype is not transient. The observed phenotype was accompanied by an increase 
in mRNA levels for growth factors, including amphiregulin (Figure 3.3), which is associated with a loss of 
ER and increased inflammatory signaling in breast cancers (26, 27). These data suggest that EMT is 
observed and that hormone-independent proliferation of ER+ cells may be linked to EMT. 
 
 
Figure 3.2: Mammary fibroblasts induce an epithelial-to-mesenchymal transition in ER
+
 breast cancer cells in 3D 
culture. Over the course of 6 days in the sandwich co-culture, MCF-7
S
 display increased mRNA levels of EMT markers 
SNAIL and SLUG with a downstream decrease in E-cadherin mRNA 
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Figure 3.3: Amphiregulin mRNA expression is increased in MCF-7 breast cancer cells in the sandwich co-culture. 
 
To confirm that the phenotypic changes in MCF-7S were due to fibroblast signaling and not 
dependent on the sandwich geometry, we employed the MCF-7M culture.  Similar to MCF-7 and MCF-7S, 
spheroids were still obtained in MCF-7M, with fibroblasts at spheroid perimeters but not inside the 
spheroids (Figure 3.4). Two seeding compositions were utilized for MCF-7M, consisting of 
fibroblast:epithelial cell ratios of 1:5 (indicating a ‘low density’ of fibroblasts) and 1:3 (indicating a ‘high 
density’ of fibroblasts). Although in these MCF-7M cultures SNAIL and SLUG mRNAs were expressed at a 
much higher levels and E-cadherin levels were decreased 2-fold or more compared to MCF-7S (Figure 
3.5), a density-dependent level is observed between the low and high fibroblast ratios. Because RNA 
was extracted for both cell types in the mixed co-culture, mRNA levels for these markers from HMF 
grown alone are also displayed. HMF basal mRNA levels of SNAIL and SLUG were elevated compared to 
MCF-7, but this basal level is only approximately 30% the level observed in the co-culture, suggesting 
that regulation of the EMT phenotype is synergistic and not dominated by one cell type. Reduction in E-
cadherin mRNA levels was also confirmed for the protein using immunohistochemical staining (Figure 
3.6). Demonstrating that the presence of HMF also alters the behavior of cancer cells, MCF-7 grown in a 
Transwell co-culture with HMF were found to be significantly (p=0.0045) more invasive compared to 
naïve MCF-7 (Figure 3.7). Comparing the mixed and sandwich culture models, we observed that 
increasing both the co-culture time and increasing the relative number of fibroblasts in the co-culture 
induced similar trends in the gene expression of EMT markers in the cancer cells. These results indicate 
that paracrine signaling is sufficient for normal mammary fibroblasts to induce EMT and increase 
invasiveness in epithelial cells.  
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Figure 3.4: Light microscopy image showing fibroblasts recruited to MCF-7 spheroids after 3 and 5 days in culture. 
 
 
Figure 3.5: A mixed co-culture was prepared at two fibroblast seeding densities, low- and high-density (relative to MCF-7). 
EMT markers are seen as with the sandwich co-culture, and there is a dose-dependent response to the fibroblast presence. 
 
 
Figure 3.6: Immunohistochemistry was used to confirm decrease in overall E-cadherin protein level and a dissociation of 
MCF-7
M
 
MCF7M (high density)
Day 3 Day 5
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Figure 3.7: co-culture with HMF significantly increases the invasive potential of MCF-7 
 
Co-culture with mammary fibroblasts down-regulates cancer cell ERα and drives hormone-independent 
proliferation 
Due to the known correlation between EMT and insensitivity to endocrine therapy, we 
hypothesized that co-culture with fibroblasts might also alter response to hormones. Our model system 
presents an opportunity to understand how EMT affects endocrine sensitivity and how the 
microenvironment influences this phenomenon. As a prelude to using the culture systems for this effort, 
estrogen response in monolayer and 3D culture was confirmed to be similar although there are gross 
morphological differences between the different culture systems (Figure 3.8). A sustained and marked 
reduction in the mRNA level of ERα in MCF-7S was observed in co-culture (Figure 3.9). Though reduced 
in abundance, the remaining ERα in MCF-7S cells was functional, as shown by the induction of the E2-
responsive genes progesterone receptor (PR) and Ki67 mRNA after treatment with this hormone (Figure 
3.10). However, while basal levels of Ki67 mRNA and cellular proliferation were increased in both co-
cultures, after 6 days of co-culture response to E2 was substantially diminished, suggesting that MCF-
7S/MCF-7M proliferation becomes increasingly hormone-independent (Figure 3.11). Accompanying this 
hormone-independent growth, tamoxifen (Tam) was no longer effective in inhibiting the growth of MCF-
7M (Figure 3.12), implying that patients with specific stromal characteristics might not respond to these 
therapies, regardless of ER status. 
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Figure 3.8: Comparison of morphology and response to E2 in 2D and 3D MCF-7 models. Response of MCF-7 cells to E2 
stimulation is similar in 2D and 3D cultures as monitored by induction of E2-response genes progesterone receptor (PR) and 
proliferation marker Ki67. 
 
 
Figure 3.9: Co-culture with human mammary fibroblasts down-regulates ERα and fosters hormone-independent growth of 
breast cancer cells. Fibroblasts down-regulate ERα mRNA levels at 3 and 6 days and this effect increases with longer co-culture 
time 
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Figure 3.10: HMF reduce the response of MCF-7 cells to E2, as measured by PR and Ki67 mRNA levels at 3 and 6 days. 
 
  
Figure 3.11: Co-culture with HMF increases the basal proliferation rate of MCF-7, and decreases the effect of E2 stimulation 
on proliferation monitored at 3 days. 
 
  
Figure 3.12: MCF-7
M
 proliferation fails to respond to increasing concentrations of E2 (left panel) and MCF-7
M
 growth is not 
inhibited by treatment with tamoxifen (right). Response in MCF-7 cells alone is shown for comparison. 
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Conditioned medium from 3D co-cultures induces EMT in breast cancer cells and also normal mammary 
epithelial cells 
After establishing above that fibroblast-epithelial interactions occur via paracrine signaling, we 
sought to elucidate the molecular components involved in greater detail by examining the culture 
medium. Conditioned medium (CM) was profiled using a protein array. Of the measured 507 proteins, 
46 were found to be upregulated five-fold or greater compared to control (Table 3.1). Notably, many of 
the upregulated proteins were members of the matrix metalloproteinase family (MMPs), which has 
been previously implicated in aggressiveness of breast cancer cells (28) and in human tumor samples 
(29). Other identified proteins included growth factors and cytokines that play a role in recruiting cells 
involved in the inflammatory response. This finding implies that fibroblasts may serve to enhance the 
systemic response involving other cell types found at the periphery of and within tumors. Functional 
classification of the secreted proteins also showed enrichment in components of chemotaxis and ECM 
remodeling (Table 3.2). To further validate the sufficiency of soluble proteins in driving phenotypic 
changes, we examined gene expression changes in MCF-7 cells treated with CM (Figure 3.13). ERα levels 
were halved in treated samples, while EMT markers SNAIL and SLUG were highly upregulated with an 
almost complete loss of E-Cadherin mRNA, confirming that the changes observed are due to secreted 
factors. 
Table 3.1: Secreted proteins identified as being increased 5-fold or higher in CM derived from co-culture compared to 
medium from MCF-7 cells alone 
 
54 
 
Table 3.2: DAVID pathway association based on secreted protein signature 
 
 
 
Figure 3.13: Treatment of cancerous and normal primary mammary epithelial cells with conditioned medium (CM) promotes 
more aggressive phenotypes and reveals a mechanism of paracrine signaling. Gene expression changes in MCF-7 cells treated 
with CM reveal a 10-fold increase in SNAIL, a 7-fold increase in SLUG, and elimination of detectable E-cadherin mRNA. The 
increase in EMT markers is accompanied by a down-regulation of ERα mRNA. 
 
To examine whether the cancer cell-fibroblast interaction might also affect adjacent normal 
epithelium, we grew normal primary human mammary epithelial cells (HMEC) with CM before 
measuring gene expression changes. Strikingly, the same EMT phenotype was observed although 
changes in cell markers of EMT were less dramatically altered in these cells compared with MCF-7 
(Figure 3.14). Based on these results, we propose that fibroblast-cancer cell interactions can induce an 
Networks pValue Genes from Active Data
Chemotaxis 7.991E-11 IL-1 beta, CCR2, GRO-3, Lck, CCL13, Galpha(q)-specific 
peptide GPCRs, Galpha(i)-specific peptide GPCRs, SDF-1, IL-
16, CCL7, GRO-2, PD-ECGF (TdRPase), GCP2
Proteolysis_ECM remodeling 1.820E-09 MMP-13, MMP-14, TIMP3, MMP-1, TIMP4, MMP-15, MMP-
24, MMP-1, MMP-25, Stromelysin-1
Inflammation_Jak-STAT 
pathway
4.161E-09 IL21R, CCR2, PDGF-R-beta, IL5RA, CCL13, PDGF receptor, IL-
2R gamma chain, IL-21 receptor, SDF-1, IL10RA, IGF-1, CCL14, 
IL-20
Proteolysis_Connective tissue 
degradation
4.951E-08 MMP-13, MMP-14, TIMP3, MMP-19, TIMP4, MMP-15, MMP-
24, MMP-1, MMP-25, Stromelysin-1
Cell adhesion_leukocyte
chemotaxis
9.863E-07 CCR2, GRO-3, Lck, CCL13, Galpha(q)-specific peptide GPCRs, 
Galpha(i)-specific peptide GPCRs, SDF-1, CCL14, CCL7, GRO-2, 
GCP2
Immune response_Th17-
derived cytokines
1.520E-06 IL-1 beta, MMP-13, SDF-1, CCL7, RANKL(TNFSF11), GCP2, 
MMP-1, Stromelysin-1
Development_Blood vessel 
morphogenesis
2.810E-06 IL-1beta, FGF8, Galpha(q)-specific peptide GPCRs, Galpha(i)-
specific peptide GPCRs, MMP-19, SDF-1, ALK-2, VEGFR-2, TIE, 
PD-ECGF (TdRPase), VEGF-D
Cell adhesion_Platelet-
endothelium-leukocyte
interactions
1.497E-05 IL-1 beta, MMP-13, PDGF-R-beta, Endoglin, PDGF receptor, 
VEGFR-2, Thrombospondin 4, TGF-beta receptor type II, 
PDGF-R-alpha
Apoptosis_Anti-Apoptosis 
mediated by external signals 
via PI3K/AKT
2.345E-05 IL-1 beta, FGF8, PDGF-R-beta, PDGF receptor, GFRalpha1, 
IGF-1, VEGFR-2, NT-3, VEGF-D, PDGF-R-alpha
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EMT in nearby normal breast epithelial as well as cancer cells via soluble protein signaling. These novel 
observations imply that the fibroblast-cancer cell environment can impact the behavior of normal 
epithelium that may act in concert with other stimuli to initiate tumors or induce progression of both 
early and later stage epithelial tumor cells toward a more aggressive state.  
 
 
Figure 3.14: After treatment of HMEC grown in monolayer culture with CM, there is an increase in gene expression related to 
EMT and growth factor release. This suggests that paracrine effects of tumor cells can impact the phenotype of nearby normal 
mammary epithelial cells. 
 
Patients with high expression of the secreted protein signature are more likely to have poor  
clinical outcomes  
We hypothesized that our in vitro secreted protein signature may be correlated with poor 
outcome in breast cancer patients. We utilized a publicly available dataset (30) comprised of 109 
patients diagnosed with Invasive Breast Cancer (IDC), pure Ductal Carcinoma in Situ (DCIS) or mixed 
diagnosis (IDC with a DCIS component) based on histology. Using the genes that code for the proteins 
identified to be upregulated on our screen, we clustered microarray data from primary tumors. Three 
primary patient clusters were found (Figure 3.15). The red cluster, characterized by elevated levels of 
MMPs and TGFβ, showed a significantly worse prognosis. Patients with high levels of the signature not 
only had a poor clinical outcome, but were also significantly more likely to be given an invasive ductal 
carcinoma (IDC) or ‘mixed’ histologic classification compared to DCIS. Further, we used ONCOMINE 
analysis to validate results across additional breast cancer datasets (31-34). This CM protein-derived 
signature was strongly correlated with invasion and poor prognosis, and was associated with the stroma 
in microdissected samples (Figures 3.16 and 3.17). The utility of this signature derived from cell culture 
models to stratify patient data based on gene expression suggests that after further work and validation, 
bottom-up protein signatures may prove useful for monitoring the dynamic states of tumor progression. 
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To our knowledge, this is the first study that utilizes a secreted protein signature to stratify breast 
cancer patient outcome.  
  
Figure 3.15: Hierarchical clustering of breast cancer patient samples based on the secreted protein signature reveals novel 
subgroups. Three classes can be distinguished, and survival analysis shows that patients in the red class (i.e. with higher gene 
expression of the signature secreted proteins) are significantly more likely to have poor outcomes, and are more likely to 
receive a diagnosis of invasive ductal carcinoma (IDC) compared to a mixed or ductal carcinoma in situ (DCIS) histological 
classification. 
 
Figure 3.16: ONCOMINE™ analysis shows that the protein signature is also overexpressed in IDC compared with DCIS in an 
independent dataset. The protein signature is also significantly correlated with the stroma of breast tumors. 
57 
 
 
Figure 3.17: Analysis of an independent dataset shows that high expression of the protein signature is correlated with the 
stroma. 
 
Hormone response can be monitored using FT-IR spectroscopic imaging 
Our data show that ER function is dynamic and ER-positive cells may not respond to endocrine 
therapies if they have undergone EMT. Given the spatially-heterogeneous nature of tumors, an imaging 
technique to record this condition is needed. While IHC techniques can provide information about the 
presence of particular proteins, they do not reveal the function of these proteins. Further, antibody-
based techniques are slow and not highly reproducible (35). Hence, we sought to apply a label-free 
imaging technique to our model 3D culture system. We used FT-IR imaging which combines microscopy 
to provide spatial information with spectral data that reveals a chemical measure of response of breast 
cancer cells to hormone or therapy. In MCF-7 cells after E2 treatment, we observed a large increase in 
the C-H vibrational region of the spectrum (Figure 3.18), commonly associated with the CH2 bending of 
fatty acids and lipids (36). These three bands (2960 cm-1, 2930 cm-1, and 2850 cm-1) are also correlated 
with fatty acyl chain peroxidation (37). Similarly, the peak at 1080 cm-1, associated with the phosphate 
backbone of nucleic acids and altered metabolic activity, is increased upon E2 treatment. Thus, we have 
directly correlated absorption pattern changes with biological changes occurring in MCF-7 cells in 
response to treatment with E2, a potent stimulator of proliferation in ER
+ cells. To our knowledge, the 
label-free imaging of this type of induced change in breast cancer has not been previously shown. 
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Figure 3.18: Fourier transform-infrared (FT-IR) spectroscopic imaging can be used to monitor hormone response in ER
+
 breast 
cancer cells. A change in FT-IR spectroscopic imaging is seen in MCF-7 cells treated with estradiol (E2), particularly in the C-H 
stretching region (3000 – 2750 cm
-1
) and in the peak associated with nucleic acids (1080 cm
-1
). However, when cells are co-
cultured with HMF, the response to hormone is lost. 
 
Next we sought to differentiate between cells having functionally active ER and those that do 
not. Samples from the mixed co-culture were imaged, and the average spectra upon treatment with E2 
were compared (Figure 3.18). Analysis of the spectra revealed that there was a loss of the chemical 
signature associated with E2 response in the co-cultured samples, corresponding to the loss of ERα and 
ERα-mediated response in MCF-7M. The fibroblast dose-response seen in mRNA levels was also apparent 
in IR spectra (Figure 3.19). The loss of E2 response is also seen in the IR spectra of CM-treated samples, 
but to a lesser extent than with the direct co-culture (Figure 3.20). The chemical signature of E2 
treatment and its loss after co-culture with HMF in 3D culture reveals that FT-IR imaging may be useful 
in determining ER function in cells in vitro.  
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Figure 3.19: The spectroscopic signature of E2 response of MCF-7 cells is based on fibroblast density. 
 
Figure 3.20: The spectroscopic signature of E2 response of MCF-7 cells is affected by treatment with CM, signifying that 
secreted factors can induce a similar change but this effect is reduced compared to co-culture. 
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A spectral signature was also associated with response to tamoxifen (Tam) (Figure 3.21). There 
is a change in peaks in the C-H stretching region of the spectrum in MCF-7 after treatment with Tam, but 
the anti-proliferative effects of Tam are specifically seen at the 1080 cm-1 peak. We have shown that the 
proliferation of MCF-7M is not inhibited by treatment with Tam using a cell-based proliferation assay, 
and here we correlate that specific phenotype to a spectral signature. While the 1080 cm-1 peak is 
significantly decreased in MCF-7 after Tam treatment, the peak is unchanged in MCF-7M. This label-free 
approach can be used to discriminate between cells that are responsive and those that are resistant to 
tamoxifen treatment. 
 
Figure 3.21: FT-IR spectroscopic imaging can be used to monitor response to the endocrine therapy tamoxifen (Tam) in ER
+
 
breast cancer cells. While there is a slight induction in peaks associated with the C-H stretching region upon treatment with 
Tam, the peak associated with nucleic acids, and therefore proliferation, is decreased in MCF-7 cells. This is correlated with the 
anti-proliferative effects of tamoxifen on ER
+
 cells. In samples that have been co-cultured with HMF, this change is not seen at 
the 1080 cm
-1
 peak, corresponding to the endocrine-resistant growth that was seen using proliferation assays. 
 
Finally, we imaged human breast tissue microarrays (TMAs) containing samples from 148 
patients in order to establish whether differences in ER status are apparent in clinical samples. Spectra 
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from the epithelium of IDC samples with high expression of ER (>80% of cells ER+) were extracted and 
compared to IDC samples with low expression of ER (<20% of cells ER+) (Figure 3.22). A Bayesian-type 
classifier was developed for the histologic discrimination of breast tissue using previously reported 
methods (16). The classifier was used to extract pixels corresponding to epithelium or fibroblast regions 
from breast cancer samples with varying levels of ER for this study and compared to determine 
signatures based on different cell types. Similar to the results observed for cellular changes in culture 
compared to tissues, several spectral markers can be translated from these 3D culture models to human 
tissue. In the epithelium (Figure 3.23), spectra from samples with high ER expression demonstrated 
similar absorbance in the C-H stretching region (3000 – 2825 cm-1) to MCF-7 3D spheroid cultures and 
the overall absorbance in this region was higher than samples with low ER expression. Strikingly, 
significant spectral differences were observed in fibroblasts from tumors with different epithelial 
characteristics (Figure 3.24). These results suggest that IR may be used to identify features in the 
stromal compartment that are associated with long-term endocrine response. Spectroscopic differences 
between human breast tumor samples with varying levels of ER expression suggest that FT-IR 
spectroscopic imaging can complement IHC analysis by providing additional chemical information about 
the function of this nuclear hormone receptor in breast tumors. 
 
Figure 3.22: Spectroscopic signatures determined using 3D co-culture models can be translated to human breast tissue 
samples. Tissue microarray (TMA) biopsy cores (1.5 mm core diameter) were IHC stained for ERα and also imaged using FT-IR 
imaging (N-H/O-H band at 3300 cm
-1
 visualized here for clarity). Images classified using Bayesian classifier are displayed as well 
to highlight the ability of FT-IR to discriminate between cell types in complex samples. Scale bar represents 250 µm. 
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Figure 3.23: Differences between epithelial pixels in patient samples with high (>80%) and low (<20%) expression of ERα can 
be seen in peaks at 1080 cm
-1
 (phosphate) and 1030 cm
-1
 (glycosidic bonds). Full spectrum (3800 – 950 cm
-1
), C-H stretching 
region (3000 – 2750 cm
-1
), and biochemical fingerprint region (1750 – 950 cm
-1
) are shown.  
 
 
Figure 3.24: Interestingly, in fibroblast-labeled pixels from patients with high or low ERα expression there are more apparent 
spectroscopic differences in the same regions. 
 
Discussion 
Our findings reveal that interactions of cancer cells with normal mammary fibroblasts induce 
hormone-independent growth and promote a more aggressive and invasive phenotype in breast cancer 
cells. Thus, fibroblasts alter the manner in which ER+ cancer cells respond to hormones by reducing the 
role of estrogen in controlling proliferation and promoting a more rapidly proliferating hormone-
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independent state. Importantly, the cross-over to hormone-independent growth is associated with an 
EMT phenotype, which has been previously correlated to invasive disease and poor prognosis (38-40). 
EMT was concurrent with the disruption of E2/ERα signaling and the appearance of more aggressive and 
invasive phenotypes. We also find ERα to be down-regulated such that it is no longer the prime 
determinant of tumor growth, underscoring this as a potential mechanism by which tumors become 
resistant to endocrine therapy. Of interest, a recent report has shown association between low ERα and 
EMT and poor prognosis in human endometrial carcinoma (41). The therapeutic implication is that 
although women may be diagnosed as ER+, some will not respond favorably to endocrine therapies 
because growth of their tumor is hormone-independent based on the nature of their tissue 
microenvironment. Therefore, it may be advantageous to simultaneously inhibit pro-inflammatory 
molecules in a fibroblast-enriched tumor microenvironment in combination with the use of anti-
estrogen or other endocrine therapies. 
  
At this stage, two directions were apparent to us – first, providing a set of molecular targets that 
could be used for diagnostic assays or drug targets, and, second, the need for a convenient method that 
can assess the entire tumor despite spatial heterogeneity found in the tumor and its microenvironment. 
In analyzing fibroblast-epithelial cell interactions for molecular targets using protein microarrays, we 
found this interaction to result in expression of a set of regulatory proteins, including M-CSF, SDF-1, and 
MMP family proteins that have been individually associated with cancer-activated fibroblasts and 
invasive disease (28, 29, 38, 42). Our time-course experiments show that these represent early signaling 
events in the fibroblast-cancer cell relationship and suggest that it is the combined external signaling of 
both fibroblasts and cancer cells that contributes to the extracellular milieu that drives an EMT 
phenotype in the cancer cells. Notably, while the presence of fibroblasts increased tumor cell 
invasiveness, the proteins secreted into conditioned medium upon interactions with cancer cells also 
greatly affected the properties of normal mammary epithelial cells. These observations imply that 
fibroblast-cancer cell interactions may put at risk nearby normal mammary epithelial cells, initiating 
early cancer-like phenotypic changes that may be relevant to indolence vs. acceleration of early stages 
of breast tumorigenesis. Our observations are supported by work in mouse mammary gland showing the 
impact of mammary stromal cells in promoting the initiation of cancer-like properties of normal 
mammary epithelial cells (43). Further, fibroblasts may be implicated in the etiology of diseases such as 
benign prostatic hyperplasia that have been associated with EMT (44). 
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Because the secreted proteins identified in these experiments are potentially clinically 
actionable, we used the protein expression data to obtain a corresponding panel of genes (iSig). Since 
the protein expression is assured, this approach helps narrow the gene signature to a functionally-
relevant and likely more effective, smaller biomarker set.  We determined that this in vitro signature 
could be used to cluster patient samples and predict prognosis. Several signatures of breast cancer 
invasiveness and poor prognosis have been reported (45, 46). These, however, come from a top-down 
approach utilizing statistical patterns found in the gene expression profiles of patient tumors. By taking 
the results of controlled in vitro experiments and comparing the data to patient genome-wide 
expression, this ‘bottom up’ approach can be used to provide mechanistic insight into tumor 
progression. Moreover, this approach relies on the ability of the tumor to interact with the 
microenvironment and, is therefore not an inherent property of the tumor cells alone. Our developed 
approach is complementary to existing subtyping and can be employed to broaden and enhance the 
present system. 
 
Finally, we utilized the novel approach of FT-IR spectroscopic imaging for determining hormone 
sensitivity in biological samples in a facile and expeditious manner. This label-free and non-destructive 
technique was able to provide chemical signatures of disease progression. We correlated gene 
expression and a loss of E2/ERα signaling with decreases in peak height in the C-H stretching region of 
the spectrum in 3D culture cell samples. These results are validated by prior observations that EMT is 
associated with changes in lipid profiles in epithelial cells (47). We also confirm that MCF-7 cells become 
resistant to tamoxifen using spectral features, primarily in the peaks associated with nucleic acids. These 
results directly correlate optical profiles to cellular behaviors and genomics. Translating the cell culture 
results to patient samples, the in vitro chemical signature was also found in invasive breast cancer 
biopsies with differing levels of ER expression. These results indicate that FT-IR imaging can potentially 
be useful, alongside IHC and molecular marker analyses, to determine ERα functionality in tissue. 
Though other imaging techniques such as positron emission tomography (PET) have been used for 
functional imaging studies before and after therapy (48), development of a similar approach at the 
microscopic scale is complicated by the need to also appreciate the morphology and spatial 
heterogeneity of cell types present in the tumor and its microenvironment. FT-IR imaging can provide 
microscopic evidence rapidly and is applicable at the time of usual post-biopsy diagnoses in pathology. 
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In conclusion, using novel approaches, we have demonstrated that mammary tissue fibroblasts 
can alter therapeutic response to anticancer agents and play a crucial role in controlling whether ER+ 
breast cancer cells respond to hormone or become resistant to endocrine therapies. Thus, the tumor 
microenvironment can result in deregulation of estrogen receptor signaling and alterations in cell 
survival signaling molecules that provide tumors with alternative proliferative and survival stimuli (49-
52).  The pro-inflammatory microenvironment that is generated as a result of epithelial-fibroblast 
interactions is sufficient to stimulate EMT in breast cancer cells and, also strikingly, in normal mammary 
epithelium. Notably, the molecules identified from this interaction are also upregulated in breast 
cancers from patients with invasive disease and predict a less good clinical outcome (26-29, 42, 54-55).  
Our findings provide new molecular insights into the microenvironment regulation of tumor behavior via 
interaction between cancer cells, fibroblasts, and nearby normal epithelial cells, and should aid in the 
development of specific inhibitors of molecular species in this cross-talk that promote early stages in 
tumorigenesis as well as cancer growth and progression to a more aggressive, therapy-resistant state. 
 
Materials and Methods  
 
Cell Culture 
MCF-7 cells were grown as previously described (27). Primary normal human mammary fibroblasts 
(HMF) were purchased from ScienCell and cultured according to their specifications (ScienCell Research 
Laboratories, Carlsbad, California, USA). Fibroblasts were used prior to passage 8 to ensure phenotype 
stability. Primary normal human mammary epithelial cells (HMEC) were also purchased from ScienCell 
and cultured according to their specifications. HMEC were used prior to passage 3 to ensure phenotype 
stability. For sandwich (non-contact) co-culture, MCF-7 cells were cultured in hormone-depleted 
medium (TM, comprised of phenol red-free basal MEM containing 5% charcoal-dextran stripped calf 
serum). 3D cultures were prepared by spreading a thin layer of growth factor-reduced phenol red-free 
Matrigel (BD Biosciences, San Jose, California, USA) in multi-well plates and seeding a low density of 
MCF-7 on top (for a 12-well plate, 100 μl of Matrigel was used and 8,000 cells were seeded per well). 
The cells were seeded in 1 ml of TM containing 2.5% dissolved Matrigel. Fibroblasts were embedded in 
600 μl of a 2 mg/ml type I collagen gel (Type I collagen from rat tail tendon, BD Biosciences, San Jose, 
California, USA) at a density of 350,000 cells/ml and prepared in 24-well plates as previously described 
(14). MCF-7 cells were grown in 3D for 5-7 days in TM before adding fibroblast layer. Fibroblasts were 
grown for two days in 3D gels before co-culture. Co-culture ranged from 3-6 days before analysis. For 
66 
 
the ‘direct’ co-culture, 100 μl of Matrigel was spread in each well of a 12-well plate and 8,000 MCF-7 
cells were seeded as before. After 5-7 days of growth in TM, HMF were seeded at a ratio of 3:1 or 5:1 
(2,700 or 1,600 HMF per well respectively). The medium was then switched to a 3:1 or 5:1 ratio of TM: 
complete FM medium (ScienCell Research Laboratories) for the duration of the co-culture. MCF-7 cells 
were grown alone as a control, and their medium was the 1:1 mix for these experiments.  
 
Proliferation Assays 
All proliferation assays were performed using the WST-1 reagent (Roche Applied Science, Indianapolis, 
Indiana, USA) as described (56). For each time-point, the medium was replaced with fresh TM:FM 
containing 10% v/v fresh thawed WST-1 reagent. After 30 min of incubation, absorbance was read at 
450 nm on a PerkinElmer Victor X Multilabel Plate Reader (PerkinElmer, Waltham, Massachusetts, USA). 
Data were normalized to the vehicle control based on cell type (for example, MCF-7 treatments were 
normalized to MCF-7 vehicle control, while 3:1 treatments were normalized to the 3:1 vehicle control) in 
Excel and plotted in GraphPad. All samples were prepared in duplicate. 
 
Invasion assays  
HMF (1x104) were seeded on the bottom of modified Boyden chambers while MCF-7 (3x104) were 
seeded on precoated filters (8 μm pore size) after membrane rehydration (BD Biosciences). Following 
incubation for 48 h at 37 °C, cells were fixed in 10 % formalin buffer and stained using crystal violet. 
Non-invaded cells on the surface of the filter were removed using a cotton swab. Invasion was 
quantified as described (56) by counting the percentage of cells that had invaded the filter compared to 
the total seeded number.  
 
Quantitative Real-time PCR 
Total RNA was isolated from cells using TRIzol (Invitrogen, Life Technologies, Carlsbad, California, USA). 
cDNA was prepared by reverse transcription with M-MuLV Reverse Transcriptase (New England Biolabs 
Inc, Ipswich, Massachusetts, USA). mRNA expression was measured using quantitative real-time PCR on 
a high-throughput ABI Prism 7900HT real-time instrument (Applied Biosystems, Life Technologies, 
Carlsbad, California, USA) using SYBR Green PCR Master Mix (Applied Biosystems) as described 
previously (57).  
 
Immunohistochemistry 
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For both immunohistochemistry and FT-IR imaging analysis, samples were fixed in freshly-prepared 4% 
paraformaldehyde for 1 h, mounted in Histogel (Thermo Fisher Scientific Inc., Waltham, Massachusetts, 
USA), and then paraffin-embedded. For paraffin embedding, samples mounted in Histogel were 
dehydrated with serial ethanol washes (50%, 70%, 80%, 95%, 100%, 100% for 3 h each) followed by 
three 2 h clearing steps in xylenes, and finally four 1 h paraffin infiltration steps (ParaPlast Plus, Sigma-
Aldrich, St. Louis, Missouri, USA).  
 
For IHC, samples were sectioned at 10 μm onto poly-L-lysine coated slides (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA). Once dry, slides were deparaffinized (2 x 3 min xylene, 1 x 3 min 1:1 
xylene/100% ethanol, 2 x 3 min 100% ethanol, 1 x 3 min 95% ethanol, 1 x 3 min 70% ethanol, 1 x 3 min 
50% ethanol, cold tap water). Antigen retrieval was performed by boiling the samples in the microwave 
for 15 min in 10 mM sodium citrate buffer (pH 6.0). Slides were blocked in Tris-buffered saline (TBS) 
containing 10% FBS overnight at 4 °C. Primary antibody was added in TBS containing 1% BSA for one 
hour at room temperature. The remainder of the protocol was performed as specified using a HRP/DAB 
detection kit (EXPOSE Mouse and Rabbit Specific HRP/DAB Detection IHC kit, Abcam, Cambridge, 
Massachusetts, USA). E-cadherin antibody was used at a dilution of 1:400 (E-cadherin 24E10 Rabbit 
mAb, Cell Signaling Technology, Danvers, Massachusetts, USA). 
 
Antibody Arrays and Classification of the Protein Signature 
Antibody Array was from RayBiotech, Inc. (L-Series 507: RayBio® Label-based Human Antibody Array 1-
Membrane). Array analyzes 507 human proteins simultaneously in two samples to examine differential 
expression. Conditioned medium was obtained from mixed (direct contact) co-cultures after 3 days and 
this was compared with conditioned medium from MCF-7 cells grown in 3D for the same length of time. 
Samples were prepared according to the manufacturer’s specifications. Protein array membrane was 
imaged with an Image Quant LAS 4010 Luminescent image analyzer (GE Healthcare, Waukesha, 
Wisconsin, USA). GO and pathway classifications of the protein signature were conducted using web-
based DAVID Bioinformatics Resources database (58) and MetaCore™ (Thomson Reuters, New York, NY, 
USA). 
 
FT-IR Imaging and Image Classification 
For cell culture samples, paraffin embedded samples were sectioned at 5 μm onto MirrIR IR-reflective 
glass slides (Kevley Technologies, Chesterland, Ohio, USA). Once dry, samples were deparaffinized in 
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hexanes for 24 h and then dried before imaging. For FT-IR imaging, a PerkinElmer Spotlight 400 
(PerkinElmer, Waltham, Massachusetts, USA) equipped with a thermal source and a raster-scanning 
linear array detector was used with a Germanium ATR imaging accessory. An NB medium apodization 
was applied, a 1 cm s-1 mirror speed was used for acquisition, and zeropadding was not used.  
 
Background scans were taken at 8 cm-1 spectral resolution. 150 x 150 μm images were collected at   
8 cm-1 spectral resolution with 16 scans per pixel and a 1.56 x 1.56 μm pixel size. Data were atmospheric 
and ATR corrected on the Spotlight, and further processing was done using ENVI-IDL. A minimum noise 
fraction (MNF) algorithm was applied on all images (59) to reduce noise in the data. Two regions were 
imaged per sample, and samples were prepared in duplicate (for a total of 4 data sets per condition). 
Because each image represented a combination of cells, Matrigel, and Histogel, a Bayesian-type 
classifier was developed as before (13) that labeled spectral contributions from cells within the image. 
Only cell spectra were plotted and compared, to reduce the influence of chemical contributions from 
the extracellular matrix and embedding material. Once spectra were classified and extracted, a baseline 
correction was applied and spectra were further normalized to the Amide I peak (1656 cm-1) for 
comparison. Spectra were plotted using OriginPro software. 
 
Data Analysis of Microarrays 
A publicly-available microarray dataset was downloaded from GEO (GSE26304) and included 31 pure 
DCIS patients, 36 IDC patients, and 42 patients with ‘Mixed’ histology (30). Data were transformed into 
GeneSpring GX 7.3 and chips and genes were median normalized and median polished.  Hierarchical 
clustering of the genes matching the 46-protein secreted signature was performed and displayed using 
Eisen Cluster and TreeView software for analysis and visualization. The 46-protein signature was 
uploaded in ONCOMINE™ (Compendia Bioscience, Ann Arbor, Michigan, USA), using the following filters:  
odds ratio >2, and P-value <0.001, epithelial versus stroma or invasive cancer versus ductal-carcinoma in 
situ and cancer type (breast cancer). The Oncomine database was also used for visualization of 
significantly associated datasets. 
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CHAPTER FOUR: DESCRIBING LABEL-FREE CHEMICAL SIGNATURES OF 3D BREAST CELL CULTURES 
USING FT-IR IMAGING 
 
Abstract 
The determination of label-free optical signatures of disease progression may improve 
diagnostic and prognostic assessment of human tumors. We used Fourier transform infrared 
spectroscopic imaging and computational methods to correlate cancerous phenotypes to label-free 
optical signatures in three-dimensional culture models of breast cancer. Using a set of cell lines that 
mimic disease progression from confined to metastatic breast cancer, we identify spectroscopic 
signatures that correspond to each stage. We also discriminate between cells that are tamoxifen 
sensitive and tamoxifen resistant, and show how fibroblasts alter this signature. Finally, we determine 
the degree of heterogeneity between cells found in the same tumor spheroid and how this determines 
response to hormones and the presence of fibroblasts in 3D culture. Our findings highlight the use of FT-
IR imaging and multivariate analysis for the understanding of advanced and heterotypic in vitro models 
of disease. 
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Introduction 
Recently, the National Cancer Institute asked the question: How can the physical properties of 
tumors, such as a cell’s electrical, optical or mechanical properties, be used to provide earlier or more 
reliable cancer detection, diagnosis, prognosis, or monitoring of drug response or tumor recurrence? 
This question was raised in response to the three decades of work that has shown that it is not only the 
genetic nature of a cancer cell that determines its outcome but rather the intricate balance between 
genetics and environment (1-5). With the goal of developing novel diagnostic tools or prognostic 
markers, recent efforts have highlighted the correlation of optical signatures to cancer progression (6-8). 
An emerging technique in this field is the use of vibrational spectroscopy coupled with microscopy, or 
microspectroscopy (9-11). Using Fourier transform infrared (FT-IR) or Raman imaging is advantageous 
over other imaging methods because label-free optical signatures that contain chemical information at 
each pixel can be determined. Here, we explore the use of FT-IR to identify signatures of cancerous 
phenotypes in advanced cell culture models.  
 
Both tumors and normal tissues are known to be heterogeneous in gene expression and 
phenotype (12). However, most molecular methods including the ‘-omics are bulk measurements—a 
population average of hundreds to millions of cells. Imaging can be used to determine the degree of 
heterogeneity of in vitro models of disease or in human tissues. The most common approach is to look 
at the distribution of one or more markers of disease phenotype, either expression of a protein, DNA, or 
RNA. These approaches are limited because markers must be profiled individually. Multiplexing is 
available with immunofluorescence but the number of markers is constrained to the microscope setup, 
the availability of different flavors of fluorophores, and cross-reactivity of antibody-based labels. Thus, 
using label-free imaging based on the inherent chemical differences is advantageous for working with 
heterogeneous samples. FT-IR spectroscopic imaging was used here to put bulk molecular 
measurements in the context of cellular heterogeneity. 
 
There are some challenges associated with the analysis of FT-IR images. This approach generates 
a three-dimensional dataset in which an image is formed where each pixel contains a spectrum of 
chemical information (Chapter 1). Further, FT-IR is extremely sensitive to chemical changes. Parsing out 
spectroscopic signatures of cancerous phenotypes is alleviated by good experimental design, consistent 
sample preparation, and data processing techniques that can reduce the dimensionality of the dataset 
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and classify or cluster samples based on spectral similarities. Here, we combine these approaches to 
correlate cellular phenotypes to label-free chemical signatures. 
 
Consistent sample preparation is essential for describing chemical signatures of disease because 
IR detects changes in molecular bonds. Cell cultures are typically fixed physically or chemically to retain 
structural and molecular information. However, fixation by drying or freezing can destroy cellular 
architecture while chemical fixation can alter molecular components. Previous studies have pelleted 
cells to avoid this problem, but in this instance spatial information is lost (13). Recently, it has been 
shown that formalin fixation and paraffin embedding does maintain the lipid, phosphate, and protein 
profiles of cells (14). Because this is the standard sample preparation used in hospital pathology 
laboratories, this procedure was used for experiments described herein. 
 
Spectral features identified in cells with increasingly cancerous phenotypes can be correlated to 
changes in proteins, lipids, and nucleic acids. The most prominent features related to proteins are the 
bands at amide II (1545 cm-1) and amide I (1650 cm-1), corresponding to amide groups (CO-NH) (15). 
Alterations in these peaks have also been associated with changes in protein conformation or secondary 
structure (16). Proteins may also contribute to the absorbance in bands in the 2850 - 2960 cm-1 region 
due to the presence of methylene (CH2) and methyl (CH3) groups found in both proteins and lipids (17). 
The PO2
- phosphodiester group of nucleic acids has vibrational modes at 1220 cm-1 (symmetric) and 
1080 cm-1 (asymmetric). Although this functional group is also present in phospholipids, the carbonyl 
group of phospholipids should also be observed at 1740 cm-1 if these are abundant in the sample of 
interest (18). Peaks corresponding to lipids cannot be unambiguously designated as there are spectral 
contributions from proteins in the same region (2850 – 2960 cm-1). Therefore, the spatial distribution of 
peaks in this region should be assessed using imaging (19). Information about chemical changes in 
heterogeneous can be accomplished by performing controlled experiments thereby directly correlating 
cellular phenotype and molecular profiling with spectral profiles. 
 
Further, it is important to identify spectroscopic changes associated with cancerous phenotypes 
in an unbiased manner. Data processing strategies that have been used for other large datasets such as 
genome-wide studies can be used. Reducing the dimensionality of FT-IR data and finding associations 
between and within heterogeneous samples can lead to the determination of label-free spectroscopic 
signatures associated with biological changes and corresponding to disease states. Bayesian classifiers 
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have been used by our group and others for the unbiased recognition of different cellular or 
extracellular component classes in heterogeneous samples (11, 20, 21). Here, we develop a classifier to 
use with 3D cell culture samples. Principal component analysis (PCA) and unsupervised hierarchical 
clustering have also been efficacious in the determination of spectroscopic signatures of biological 
processes (22, 23).  
 
In this study, we define label-free spectroscopic signatures of cancerous phenotypes in 
heterogeneous 3D culture models of breast cancer progression. We used several approaches including 
Bayesian classification, second derivative analysis, unsupervised hierarchical clustering, and image 
analysis to differentiate between different cancerous phenotypes. Here, we highlight the use of FT-IR 
imaging for studying cancer disease progression in cell culture models. 
 
Results 
Development of a Bayesian classifier to extract cell spectra from ECM components 
Three-dimensional cultures are heterogeneous, including one or more cell types and a hydrogel 
platform that consists of a mixture of carbohydrates and proteins. The 3D cultures used in this study 
contain either epithelial cells or epithelial cells and fibroblasts and are grown in Matrigel. Matrigel is 
derived from the Engelbreth-Holm-Swarm (EHS) tumor of the mouse and has been shown to contain 
type IV collagen, laminin, heparin sulfate proteoglycan, entactin, nidogen, and fibronectin (24-28). The 
relative concentrations of laminin, type IV collagen, and heparin sulfate proteoglycan were determined 
to be 1: 0.6: 0.03 (29). Further, the 3D culture is processed by embedding first in a compound called 
Histogel before it is paraffin-embedded (30). Histogel is an inert compound similar to agarose and does 
not retain histological stains. Due to the sensitivity of FT-IR to chemical changes, both the presence of 
Histogel and Matrigel can make the analysis of heterogeneous samples complicated. Because we are 
interested in spectral contributions from the cells only, a Bayesian classifier was developed to 
computationally identify pixels that are cells compared to Matrigel or Histogel. This 3-class classifier was 
trained by labeling several thousand pixels from each class. Labeling was done manually by comparing 
visible images to IR images. A total of 45 metrics were used and these metrics were primarily based on 
ratios of peak height, peak area to height, peak area to area, and peak center of gravity. The 45 metrics 
optimized by the classifier were from an original set of 144 metrics, developed for work with breast 
tissue (31). The utility of the classifier is shown in Figure 4.1. An IR image of an acinus was taken. While 
the shape of the acinus can clearly be seen with the 1656 cm-1 peak (center panel), the classifier easily 
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identifies the cell pixels. This allows the user to quickly identify cell pixels and extract their signature in 
an unbiased way-- regions of interest (ROIs) do not need to be drawn by hand. While the classifier was 
excellent at identifying cell pixels, it performed poorly in differentiating between Matrigel and Histogel 
(Figure 4.2). However, upon inspection of the classified images as well as spectroscopic signatures of the 
individual classes (Figure 4.3), it is clear that the Matrigel and Histogel pixels are being mislabeled as 
each other. The pixels of interest are those from cells, and the classifier performs well in this case.  
 
Figure 4.1: Use of the Bayesian classifier to identify pixels from cells. 
 
Figure 4.2: Receiver operating characteristic (ROC) curve identifying the performance of the 3D cell classifier. Cells were the 
most accurately classified with 97% accuracy with the first metric. 
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Figure 4.3: Comparison of cell, Matrigel, and Histogel spectra 
 
Increasingly transformed breast epithelial cells show progressive activation in spectral signatures and 
can be used as a standard to test cellular phenotype after experimental treatment 
The MCF10A cell line is widely used as a model of normal breast epithelium due to its ability to 
form growth-arrested and polarized acini in 3D reconstituted basement membrane/Matrigel culture 
(32). These cells form structures with a cytoarchitecture very similar to that found in normal breast 
epithelium and therefore are used as a comparison to determine the effects of oncogenes or 
environmental factors on the progression of breast cancer (33, 34). We have used MCF10A cells grown 
in 3D culture to understand the interaction between breast cancer cells, fibroblasts, and normal 
epithelium during breast cancer progression from confined to invasive disease. We previously identified 
a label-free spectroscopic signature of fibroblast-activated MCF10A using FT-IR imaging (Chapter 2). We 
followed up on this study by determining signatures of controlled disease progression using a system 
based on MCF10A cells. The M1-M4 cell lines are derived from the MCF10A cell line but become 
increasingly tumorigenic and eventually metastatic. M1 are MCF10A wild-type cells, while M2 have been 
stably transfected with T24 Ha-Ras. M3 are derived from xenograft-passaged M2 cells, and these cells 
are able to generate tumors in approximately 25% of xenografts. Finally, M4 are fully tumorigenic and 
metastatic (35). The benefit of using these cells is that they all have the same genetic background—only 
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the environmental context has changed. We aimed to use these as a spectroscopic library of phenotypes 
of cancer progression. 
 
First, the cells were grown on IR-reflective slides and imaged in the Attenuated Total 
Reflectance (ATR) mode. This was done to determine any basal spectroscopic differences between the 
cells when grown in monolayer culture. Upon comparison of several hundred cells for each cell line, 
spectroscopic differences can be seen (Figure 4.4). In particular, the C-H stretching region is notable 
(Figure 4.5). There is a gradual increase in the absorbance of the peaks in this region as the cells become 
more tumorigenic. The peaks in this region correspond to the stretching modes of CH2- and CH3 bonds 
and are associated with changes in fatty acid metabolism (36). We have previously shown these peaks to 
be relevant in the response of ER+ breast cancer cells to hormone (37). Differences in M1-M4 cell 
spectra were also seen in the fingerprint region (Figure 4.6), although these changes are more subtle. 
Importantly, the cell lines have distinct spectroscopic signatures. 
 
Distribution of one peak in the C-H stretching region was analyzed and compared across the cell 
lines (Figure 4.7). We found that the absorbance at 2930 cm-1 is increasingly distributed in the cytoplasm 
at the edges of the invasive cell line M3 and the metastatic line M4, compared with the less invasive M2 
and non-tumorigenic M1. These images correspond to metabolic activity at the leading edges of invasive 
cells, and suggests that distribution of this peak may be used to assess invasive potential in more 
physiologically-representative systems.  
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Figure 4.4: Spectroscopic differences between M1, M2, M3, and M4 cells grown in monolayer culture. 
 
 
Figure 4.5: Investigation of the C-H stretching region reveals a distinct pattern in transformation state. Increases in 
absorbance at the three peaks in this region is correlated to cells that are more invasive and metastatic. 
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Figure 4.6: In the fingerprint region, spectral differences are more subtle. 
 
Figure 4.7: Distribution of the 2930 cm
-1
 band, associated with fatty acids and metabolism, in M1, M2, M3, and M4 
monolayer samples. Scale bar represents 25 µm. 
 
The MCF10A cells are widely used for their ability to form growth-arrested spheroids when 
grown in 3D culture. M1-M4 cells were grown in 3D culture, and the morphology of the cell types varies 
drastically and corresponds to disease state (Figure 4.8). M1 cells form polarized acinar structures. M2 
also form spheroid structures with defined edges but are considerably larger than M1 acini. M2 also 
appear to have a larger hypoxic core. M3 cells are the most proliferative and invasive when grown on 
Matrigel. While they have the most metastatic phenotype in a xenograft model, M4 are the least robust 
when grown in 3D culture. Rather, they form multicellular structures that quickly become dissociated. It 
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has been previously shown that 3D breast cultures are more representative of human disease than 
monolayer cultures (38) and it is for this reason why we continued the FT-IR study using the M1-M4 in a 
3D model. 
  
Figure 4.8: Phase contrast microscope images show differences in size and morphology of M1, M2, M3, and M4 cell spheroids 
after 7 days of growth. Scale bar represents 50 µm. 
 
First, we compared the spectroscopic signatures of M1-M4 cells grown in 2D versus those grown 
in 3D. The second derivative of the normalized average spectra are depicted in Figure 4.9. The second 
derivative was used to identify differences between samples and can be used to display more subtle 
differences compared to looking at the raw spectra alone. All multivariate analyses were done using 
second derivative spectra. It is clear from the spectra that the M3 and M4 cells are very similar in 2D and 
3D and are distinct from M1 and M2 cells. To compare the second derivative spectra in an unbiased 
manner, unsupervised hierarchical clustering (Figure 4.10) was performed on the complete spectral 
range (4000 – 750 cm-1). In agreement with visual inspection of the spectra, the 2D and 3D comparisons 
for M3 and M4 cell lines clustered together. Different culture conditions of M1 and M2, however, did 
not cluster together. These results indicate that the chemical nature of M3 and M4 cells may be less 
sensitive to culture conditions, relating to their invasive properties. The mechanical properties of tissue 
culture plastic may provide an additional stimulus to drive tumor progression, corresponding to the 
increased stiffness seen in vivo surrounding tumors (39, 40).  
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Figure 4.9: Analysis of second derivative spectra for M1-M4 cells grown in monolayer and 3D culture. 
 
Figure 4.10: Unsupervised hierarchical clustering of average second derivative spectra shows that spectroscopic differences 
are maintained when the cells are grown in 3D culture. 
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Previously, we had determined that M1 cells (MCF10A) show an activated phenotype upon co-
culture with cancer-activated fibroblasts (Chapter 2). This activation profile could be distinguished using 
FT-IR imaging and showed differences in the C-H stretching region as well as at the 1080 cm-1 peak, 
associated with phosphate stretching of nucleic acids. We have previously shown that the method used 
to activate fibroblasts, either through treatment with the growth factor TGF-β1 or through co-culture 
with MCF-7 breast cancer cells, alters the spectroscopic signature of activated fibroblasts (41). We 
aimed to compare the spectroscopic signatures of fibroblast-activated M1 based on the method by 
which the fibroblasts were activated. This study will improve the understanding of the interaction 
between activated fibroblasts and breast epithelium.  
Human mammary fibroblasts grown in 3D collagen gels (41) were activated by treating with 1.5 
ng/ml TGF-β1 or co-culturing with MCF-7 for one week. Activated fibroblasts were subsequently co-
cultured with M1 cells for 24 or 48h before fixation and paraffin embedding. ATR FT-IR images were 
taken and cell spectra were extracted from the images using the Bayesian classifier described previously. 
We find clear distinctions between the M1 co-cultured with the differently-activated fibroblasts (Figure 
4.11). In the C-H stretching region, the different fibroblast treatments were most similar to one another 
(Figure 4.12). However, it appears that a longer co-culture time decreases absorbance in the peaks in 
this region. When the fingerprint region is analyzed, however, absorbance at the peak associated with 
nucleic acids is increased the most after co-culture for 48 hours with TGF-β activated fibroblasts (Figure 
4.13). Our results indicate that the treatment conditions of the fibroblasts impact the spectroscopic 
signatures of M1 after co-culture. 
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Figure 4.11: Comparison of spectral signatures for M1 acini co-cultured with HMF activated with TGF-β (+T) and those co-
cultured with HMF activated by MCF-7 co-culture (+M). 
 
 
Figure 4.12: There are clear differences both in the two activation strategies that can be seen in the M1 response to HMF+. 
Increasing the length of co-culture time in both conditions decreases overall absorbance at these peaks. 
 
3750 3500 3250 3000 1750 1500 1250 1000
0.0
0.2
0.4
0.6
0.8
1.0
1.2
A
b
s
o
rb
a
n
c
e
Wavenumber (cm-1)
M1 HMF+T 24h
M1 HMF+T 48h
M1 HMF+M 24h
M1 HMF+M 48h
3000 2950 2900 2850 2800
0.0
0.2
0.4
A
b
s
o
rb
a
n
c
e
Wavenumber
M1 HMF+T 24h
M1 HMF+T 48h
M1 HMF+M 24h
M1 HMF+M 48h
87 
 
 
Figure 4.13: M1 acini co-cultured with TGF-B activated HMF have increased absorbance in the 1080 cm
-1
 peak associated with 
nucleic acids. 
 
Tamoxifen resistant cells and induced tamoxifen resistance in ER+ cells can be correlated to spectroscopic 
signatures 
We previously demonstrated that FT-IR can be used to determine response to hormones in 3D 
breast cancer cells (37). One of the targeted therapies given to patients with estrogen receptor-positive 
(ER+) breast cancer is tamoxifen, but up to 30% of patients experience therapeutic resistance within five 
years (42, 43). Having found a signature of hormone response, we aimed to determine a label-free 
spectroscopic signature of tamoxifen resistance. A tamoxifen resistant cell line (TamR) was derived from 
MCF-7 cells through the long-term treatment with trans-hydroxytamoxifen (previously described in 
Reference 44). These cells were grown in 3D culture and imaged in the ATR mode of FT-IR. Their spectral 
signatures are compared to those of MCF-7 cells in Figure 4.14. TamR cells have a distinct spectroscopic 
signature, but when the signature is compared across samples, there is significant heterogeneity seen in 
the TamR cells compared to MCF-7, particularly in the C-H stretching region (Figure 4.15). The fingerprint 
region of the spectrum is unremarkable. Cancer cells have heterogeneous phenotypes, and it is likely 
that not all TamR cells are identical. The spectra displayed are an average of hundreds of cells. When the 
spectra are compared across independent biological replicates, heterogeneous populations may appear 
different.  
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Figure 4.14: MCF-7 and Tam
R
 have unique spectroscopic signatures. 
 
 
Figure 4.15: C-H stretching region comparison of two MCF-7 samples and two Tam
R
 samples. 
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Next, both MCF-7 and TamR cells were treated with 10-8 M tamoxifen (Tam) for 24 hours. This is 
known to be antiproliferative to MCF-7 cells in 3D culture (44). Normalized spectra and second 
derivative spectra from the C-H stretching (left) and fingerprint (right) regions were compared across 
conditions (Figure 4.16). Two independent biological replicates are displayed. While the MCF-7 samples 
are very similar in the response to Tam treatment, the TamR cells respond differently. Upon treatment 
with Tam, TamR cells show reduced absorbance in the C-H stretching region and relatively little change 
in the fingerprint region. These results are inconclusive in studying the effects of tamoxifen resistance 
using FT-IR imaging. 
 
Figure 4.16: Spectroscopic (top) and second derivative (bottom) analysis for C-H stretching and fingerprint spectral regions 
upon treatment with Vehicle (Veh) or Tamoxifen (Tam) in MCF-7 or Tam
R
 cells. Spectra from biological replicates are 
displayed. 
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Because we had previously shown that co-culture with HMF drastically alters spectroscopic 
signatures of breast cancer cells (37), we compared TamR cells with and without co-culture using the 
same 3D model system. Briefly, TamR cells were seeded at low density on Matrigel and grown for 6 days 
to form cancer spheroids. Normal primary human mammary fibroblasts were added on day 3 of culture 
for a total co-culture time of 3 days. The cells were in a ‘mixed’ type co-culture, and fibroblasts were 
localized to the edge of the spheroids. Co-cultures were grown in hormone-depleted medium as 
previously described (37). On the third day of co-culture, cells were treated with 10-8 M E2, 10
-8 M Tam, 
or vehicle control (ethanol). Cultures were fixed with 4% paraformaldehyde after 24 hours before 
paraffin embedding. Samples were imaged as described previously. We found that co-culture with HMF 
significantly impacts the spectral signatures of TamR cells (Figure 4.17). Further, HMF alter the response 
of TamR cells to treatment with E2 or Tam. While the basal level of absorbance in peaks in the C-H 
stretching region is higher in co-cultured TamR, treatment with tamoxifen is enhanced by the presence 
of HMF. Not surprisingly, treatment with E2 reduces the absorbance in these peaks. Changes in the 
fingerprint region are less substantial (Figure 4.18). These results give us an insight into how stromal 
cells may influence tamoxifen resistance, possibly even enhancing cancerous phenotypes upon 
treatment with Tam.   
 
91 
 
 
Figure 4.17: Co-culture with HMF alters spectroscopic signatures of Tam
R
 cells. Profiles of cells before and after treatment are 
also changed upon co-culture. 
 
Figure 4.18: Co-culture with HMF induces changes in the response of Tam
R
 cells to E2 and Tam in the C-H stretching region. 
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Figure 4.19: Co-culture with HMF induces changes in the response of Tam
R
 to E2 and Tam in the fingerprint region. 
 
Analysis of FT-IR images can be used to determine cellular heterogeneity within 3D spheroids 
It is understood that cells in tumors have heterogeneous phenotypes. Cells grown as spheroids 
in 3D culture are also heterogeneous, and it has recently been shown that even within the same 
spheroid there are phenotypic differences between cells (45). These principles have implications for the 
study of drug efficacy and treatment in patients, but they highlight the importance of using appropriate 
experimental models for initial drug studies. While cells grown in 3D as spheroids are more 
representative of cells in the human body than cells grown on tissue culture plastic, the kinetics of drug 
delivery are different. Cells will respond differently both as a function of their phenotypic expression and 
also the concentration of the drug that reaches the cell membrane. Both of these variables are 
dependent on the cell’s location within the spheroid.  
 
We have previously determined a spectroscopic signature of hormone response in MCF-7 
spheroids. Next, we analyzed the IR images to determine which cells had the most robust response to 
treatment with E2. While the cells on the outside of the spheroid should have the largest response, we 
wanted to map the signature across the diameter of the spheroid. This allowed us to determine the 
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penetration of E2 into the cell mass and assess the phenotypic heterogeneity between MCF-7 cells 
grown in the same 3D culture conditions.  
 
Images were first analyzed by drawing a series of boxes across the diameter of the spheroid, 
both lengthwise and widthwise. Each box had a length of 7.8 μm and contained 20 pixels for 
consistency. These boxes were labeled as regions of interest (ROIs) and average spectra were calculated 
for each box. Areas from either side of the spheroid were compared first (Figure 4.20 and 4.21). The 
spectra do not significantly change across the spheroid in either direction. In the center of the spheroid, 
the spectra do not change significantly (Figures 4.22 and 4.23). 
  
Figure 4.20: Spectral changes across MCF-7 spheroid. 
 
Figure 4.21: Spectral changes across MCF-7 spheroid. 
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Figure 4.22: Spectral changes within an MCF-7 spheroid. 
 
Figure 4.23: There are very subtle spectral changes within MCF-7 spheroids. In the very center of the spheroid (gold and 
crimson curves, left panel), there is a slight decrease in absorbance in the C-H stretching region. 
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While there are minimal differences across cells in a spheroid when treated with a vehicle 
control, treatment with E2 elicits a significant increase in three prominent peaks found in the C-H 
stretching region (Figure 3.18). We hypothesized that the cells on the outside, being exposed to the 
highest concentration of E2, should show the greatest response upon treatment. As shown in Figures 
4.24 and 4.25, this is the case. Pixels from the outer region of the spheroid show increases in absorbance 
at 2960 cm-1, 2930 cm-1, and 2850 cm-1. Surprisingly, this signature is lost at approximately 32 μm from 
the border of the spheroid (Figure 4.25). These results confirm cellular heterogeneity in response to E2 in 
multicellular tumor-like spheroids.  
 
Figure 4.24: Response of cells within an MCF-7 spheroid to E2. Comparison of cells from the border to the middle. 
 
Figure 4.25: Signature as a function of distance into the spheroid. 
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The spectroscopic signature of hormone response is also diminished upon co-culture with 
human mammary fibroblasts. Fibroblasts secrete factors that downregulate ERα and switch the cells to 
hormone-independent growth (37). We used image analysis to determine whether all cells in the 
spheroid displayed this phenotype or if this was related to proximity to HMFs. We also aimed to 
determine how far the fibroblast influence extended into the spheroid. Surprisingly, we found that in 
the control, cells that were not in contact with fibroblasts had the same spectral signature as cells grown 
in monoculture (Figure 4.26). When MCF-7 were in contact with HMF, however, the spectral signature is 
lost. The effect of the fibroblasts was seen approximately 39 μm into the spheroid. These results confirm 
that fibroblasts are responsible for producing changes in the spectroscopic signature. Further, 
fibroblasts have a far-reaching and sustained effect on breast cancer spheroids. Upon treatment with E2, 
the signature of response is lost when cells are in contact with HMF, and it is further diminished in the 
center of the spheroid (Figure 4.27). Taken together, these results show that FT-IR spectroscopic 
imaging can be used to determine drug delivery and efficacy in heterogeneous samples. 
 
 
Figure 4.26: Effect of fibroblast proximity on E2 response across spheroid. 
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Figure 4.27: The effect of fibroblasts extends approximately 39 µm into the cell spheroid, as measured by the response to 
treatment with E2 as a function of distance. 
 
Discussion 
We have shown that it is advantageous to use 3D models to study breast cancer cell phenotypes 
as disease progresses, how cell activities are altered by co-culture with fibroblasts or cancer-activated 
fibroblasts, and in response to hormone or therapies. Using a combination of FT-IR imaging and 
unbiased data analysis techniques, we have determined several spectroscopic signatures of cellular 
transformation. 
 
Bayesian classifiers have been used by our lab and others to computationally segregate IR 
images of heterogeneous samples into pixels belonging to different ‘classes’. This has enabled the 
development of a new field of digital pathology. Vibrational spectroscopy generates a large amount of 
information that can be used to train algorithms for the specific correlation of spectral signatures to cell 
types (13,19,22), the presence of histological markers (21), or disease states (10,11,20,23). Our group 
and others have shown that the state and dynamics of cellular transformations associated with cancer 
progression can be monitored using this technology (23,37,41). The use of classification and 
spectroscopic signatures is relatively unbiased and is less prone to the experimental error associated 
with using histologic stains. We showed that a Bayesian classifier could also distinguish between cells 
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and hydrogel constructs in a 3D cell culture model. The study of advanced cell culture models will 
benefit from an improved and unbiased method for analysis. As cultures become increasingly 
sophisticated with the addition of other cell types and additional extracellular matrix components, 
spectroscopic imaging can be used to identify contributions from these varied environmental factors.  
 
While spectroscopic imaging generates very rich datasets and is highly sensitive to chemical 
changes, these benefits also create challenges in the analysis for biological understanding. Multivariate 
analysis or dimensional reduction techniques should be used to identify differences between and within 
samples. This is especially true for samples involving cells grown in in vitro systems. Cells are 
phenotypically diverse – both normal and cancerous cells are heterogeneous (12,45). Most molecular 
analyses are done in bulk; averages of the molecular contributions of hundreds or thousands of cells are 
taken. Imaging is the best way to identify heterogeneity across and between samples. We used two 
techniques to adjust for the sources of variance in IR images of biological specimens. First, we analyzed 
the second derivative of normalized average spectra of samples. Using the second derivative can aid in 
the identification of subtle changes in peak height or location (peak shift). Further, this can be used to 
identify small peaks that are overwhelmed by broader peaks with higher absorbance. We used second 
derivative spectra to analyze how tamoxifen resistant cells differ from other ER+ breast cancer cells that 
are sensitive to tamoxifen. To further understand similarities and differences between samples, we used 
unsupervised hierarchical clustering of the second derivative. This technique can be used to determine 
how closely related two samples are, based on similarities in the spectroscopic signatures. We used it to 
determine the similarities between M1, M2, M3, and M4 cells grown in monolayer culture versus 3D 
culture. We found that M3 and M4 cells are less sensitive to their culture conditions with regard to their 
spectral signatures. M1 and M2 cells are phenotypically similar and while M2 are tumorigenic neither is 
invasive. Our results indicate that M2 may need an additional hit of a stiffened environment to display 
an invasive chemical signature. 
 
Finally, analysis of IR images reveals that the distribution of chemical bonds within and across 
biological samples is varied and can be correlated with cellular phenotypes. When M1, M2, M3, and M4 
cells were analyzed, an increased distribution of a peak associated with fatty acids/lipid metabolism was 
found at the edges of invasive cells. This trend increased as the cells became progressively more 
invasive. IR imaging has been used previously to monitor metabolically active cells, and we have 
correlated the spectroscopic signature of active metabolism with that of an enhanced cancerous 
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phenotype. IR images of spheroids were also analyzed to determine the heterogeneity across an 
individual spheroid of breast cancer cells. We found that hormone response in these cells was primarily 
found at the edges of the spheroids. Further, we found that fibroblasts affect the signature of hormone 
response and have a far-reaching effect on cells within the spheroid. 
 
Our preliminary results have demonstrated the utility of FT-IR imaging in analysis of cancerous 
phenotypes in 2D and 3D cell culture. By combining classification schemes to perform an unbiased 
segregation of pixels in heterogeneous samples, multivariate analysis and dimensional reduction 
techniques, and rigorous image analysis, we have identified label-free spectroscopic signatures of 
phenotypes that correlate with disease progression and therapeutic resistance in human breast cancer 
cells. These studies highlight the need to use a combination of strategies for utilizing the rich datasets 
generated from FT-IR imaging in order to understand the molecular mechanisms driving cellular 
phenotypes in heterogeneous samples.  
 
Materials and methods 
Cell Culture 
Cell culture protocols (maintenance in monolayer culture and assays in 3D culture) were done as 
described in Chapters 2 and 3. Additionally, the M1, M2, M3, and M4 cell lines are based on the MCF10A 
parental line (35). M1 and M2 are cultured the same as MCF10A, while the M3/M4 lines are grown in 
DMEM/F12 supplemented with 5% Horse Serum and 1% Pen/Strep without other additives. TamR cells 
were grown as previously described (44).  
 
Sample Processing 
 Cells grown as monolayers on MirrIR slides were fixed for one hour in 4% paraformaldehyde, 
washed twice in phosphate buffered saline (PBS), and then washed twice in sterile-filtered water twice 
to remove PBS. Samples were dried in a biosafety cabinet for at least 24 hours before imaging. Cells 
grown in 3D were processed as previously described. Briefly, samples were fixed in 4% 
paraformaldehyde, embedded in Histogel (Thermo Scientific), and then dehydrated and paraffin 
embedded. Samples were sectioned at 5 μm onto MirrIR slides for FT-IR imaging. Prior to imaging, slides 
were deparaffinized by soaking in hexane for 24 hours with gentle stirring. After deparaffinization, slides 
were left to dry before imaging. 
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FT-IR Imaging and Data Analysis 
 All imaging for this study was done in the Attenuated Total Reflectance mode using a 
PerkinElmer Spotlight 400. This instrument was described previously. Several 150 μm x 150 μm regions 
were imaged on each sample at a spectral resolution of 8 cm-1 with 16 co-additions with a pixel size of 
1.56 μm x 1.56 μm and an interferometer speed of 1.0 cm/s. Background spectra were collected at a 
spectral resolution of 8 cm-1 and 120 co-additions.   
 
After background and ATR corrections were done on the instrument, data was processed further 
using the ENVI-IDL software and in-house functions developed by our lab. First, a minimum noise 
fraction (MNF) reduction technique was used to minimize sources of noise in the data (46). The Bayesian 
classifier was run on MNF-corrected data to identify cell pixels. Data were baseline corrected and then 
average spectra of the cells from each sample were calculated and exported. When images were 
analyzed for spectral differences across the sample, regions of interest were drawn and baseline-
corrected/classified average spectra of individual regions were calculated and exported. Average spectra 
were normalized to the Amide I peak (1656 cm-1) and plotted in Origin Pro 8.5 (OriginLab, Northampton, 
Massachusetts, USA). Second derivatives were calculated and plotted in Origin Pro. Matlab (MathWorks, 
Natick, Massachusetts, USA) was used for unsupervised hierarchical clustering of normalized second 
derivative spectra. 
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CHAPTER FIVE: A SPECTROSCOPIC SIGNATURE OF ERα PRESENCE, LOCALIZATION, AND 
FUNCTION IN BREAST CANCER CELLS 
 
Abstract 
Estrogen receptor- (ER) is an important biomarker for the prognosis and therapeutic 
prediction of breast cancer. Patients who are ER positive may benefit from targeted endocrine 
therapies. However, up to 30% of patients will become resistant to endocrine therapy within five years 
of treatment, while others fail to respond at all. The current gold standard for the detection of ER is 
the use of immunohistochemistry to detect nuclear localization of the protein. While this describes the 
presence of the protein, it does not allow the pathologist to determine its function. This is a critical 
distinction to make with regards to choosing the appropriate therapeutic intervention. We recently 
reported that when breast cancer cells interact with mammary fibroblasts, ER protein is 
downregulated and growth of the cancer cells becomes hormone-independent and resistant to the 
endocrine therapy tamoxifen. We also showed that a label-free imaging technique, Fourier transform 
infrared (FT-IR) spectroscopic imaging, can be used to monitor hormone response in 3D culture. Here, 
we expand on our previous results and describe a spectroscopic signature of ER protein in MCF-7 cells 
through a knockdown study. Further, we also examine breast invasive ductal carcinoma biopsies with 
varying levels of ERα expression to monitor this signature in patient samples. 
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Introduction 
 Estrogen receptor breast cancers are the most commonly diagnosed cancers in the United 
States, with approximately 75% of the 232,340 new cases in the US being diagnosed as ER+ each year (1). 
Presence of estrogen receptor alpha (ERα) was described as an important biomarker for the prediction 
of outcome and response to endocrine therapies over thirty years ago (2). Estradiol- and progesterone-
receptor assays were used to assess the patient’s receptor status on the basis of the interaction 
between radioactive-labeled hormone and the patient’s tissue (3). It was not until the late 1990s that 
using immunohistochemistry to assess the patient’s ER status became standard in pathology labs. It was 
reported in a large study that immunohistochemistry was superior to the ligand binding assay in terms 
of ease, safety, cost, and ability to predict response to adjuvant endocrine therapy (4). Use of 
immunohistochemistry to determine ERα status is the current gold standard in pathology. 
 While the use of immunohistochemistry to determine hormone status is significant for the 
prognosis and assignment of therapies for breast cancer, approximately 30% of patients who receive 
endocrine therapy will become resistant within five years, while others fail to respond at all (5-7). We 
have previously shown that the function of ERα is dynamic (Chapter 3 and Reference 8) and may still be 
present and identified using immunohistochemistry while its role in promoting tumor progression is 
minimized. We generated ER+ breast cancer cells whose growth was controlled through a growth factor-
mediated pathway. These cells were resistant to treatment with tamoxifen. Thus, it would be 
advantageous to develop an assay to determine a patient’s receptor status that couples the localization 
of immunohistochemistry with a measurement of the receptor activity.  
 Recent reports have shown the efficacy of using PET-based challenges to determine ERα 
function in vivo (9,10). However, we aimed to develop a label-free microscopy-based method of 
determining ERα presence and function in human breast cancer cells and then paraffin-embedded 
(FFPE) human breast cancer tissue specimens due to the high spatial localization (on the order of 
micrometers) and ease of utility in the current clinical pathology workflow. Previously, we reported a 
signature of hormone response in MCF-7 breast cancer cells using Fourier transform infrared (FT-IR) 
spectroscopic imaging (Chapter 3). FT-IR is highly sensitive to chemical changes and has been used to 
determine label-free signatures of disease progression in cells (11-14) and tissues (15-17). Another 
benefit is the use of computational approaches to classify samples based on spectroscopic signatures 
(Discussed in Chapter 4). Thus, we propose the use of FT-IR to study estrogen receptor presence and 
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function because it is label-free, can monitor dynamics in protein function, and information can be used 
along with computational algorithms in the new field of digital pathology.   
Results 
Establishing a gradient of ERα expression 
 We aimed to determine a label-free spectroscopic signature of ERα expression. To obtain 
samples with a large range of ERα expression, a gradient was established. To do this, MCF-7 cells were 
transfected using an siRNA against the F domain of ERα (18). Because this is not a stable transfection, 
the siRNA will lose its effect as the cells begin to proliferate. Cells were transfected for 72 hours with 
siRNA and then the media was changed back to a hormone-depleted growth medium. Samples were 
harvested 24, 48, or 72 hours later. A sample was also taken immediately after knockdown (timepoint 
0). A western blot was used to confirm knockdown (Figure 5.1). 
 
Figure 5.1: A gradient of ERα expression is established after knockdown and recovery. 
 
 IR spectra across each sample were averaged and compared for the control and knockdown 
samples (0h timepoint) first in order to establish a baseline of the presence of ERα in the IR spectrum. 
Upon knockdown, changes were induced across the spectrum and this was consistent for multiple 
independent biological replicates (Figure 5.2). Notably, absorbance of peaks in the C-H stretching region 
was reduced (Figure 5.3). We had previously shown that when ERα is downregulated in MCF-7 cells 
through the interaction with mammary fibroblasts; a loss in the hormone response signature was seen 
using FT-IR (Chapter 3). This signature was primarily seen in the C-H stretching region. Further, reduction 
in peaks associated with nucleic acids (Figure 5.4) was also observed, highlighting the role of ERα in 
providing a proliferative stimulus in MCF-7 cells. 
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Figure 5.2: Spectroscopic differences between control and knockdown samples. 
 
Figure 5.3: Reduction in absorbance at peaks in the C-H stretching region was observed. This is consistent with previous 
results (Chapter 3). 
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Figure 5.4: Reduction in the absorbance of peaks associated with nucleic acids was observed after knockdown. 
Identifying a label-free spectroscopic signature of nuclear ERα expression 
 Upon treatment with estradiol (E2), ERα is localized to the nucleus (Figure 5.5, Adapted from a 
study described in Chapter 3) (19). We aimed to strengthen the IR signature of ERα expression by 
monitoring it in its active form. The same knockdown gradient was repeated, but the samples were 
treated with either E2 or a vehicle control (Veh) for 24 hours before fixation. We have previously used 
ATR FT-IR to discriminate between nuclear and cytoplasmic activity (11). In IR images of MCF-7 cells, the 
nucleus can be easily discerned using the symmetric phosphate stretching (1224 - 1236 cm-1) peak 
associated with nucleic acids (Figure 5.6). 
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Figure 5.5: ERα is localized to the nucleus upon treatment with E2 in MCF-7 cells. 
 
 
Figure 5.6: The nucleus can easily be identified using the 1236 cm
-1
 peak (symmetric phosphate stretching). 
First, images for the knockdown and control samples were analyzed to determine if the peaks 
used for normalization and labeling of the nucleus were altered upon stimulation with E2. We found that 
the Amide I peak was unaffected by treatment in both control and knockdown samples (Figure 5.7). This 
confirmed our use of this peak for normalization, as absorbance would be uniform across the sample 
and between treatments. Then, the 1236 cm-1 peak, used for labeling the nucleus, was analyzed. It is 
relatively unchanged in the control sample, but is affected in the knockdown sample (Figure 5.8). This 
result confirmed that we would be able to use IR to investigate spectroscopic signatures of ERα activity 
in the nucleus of MCF-7 cells. 
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Nuclear pixels were labeled by thresholding of the 1236 cm-1 peak. While ATR measurements 
will include not only the nucleus but also the part of the cell that lies directly above it, the primary 
contribution to the spectra will come from the nucleus itself. Cell nuclei for each sample were analyzed 
individually in each condition. We confirmed that in the control samples, there is a signature of 
hormone response to E2 treatment in peaks in the C-H stretching region (Figure 5.9, right) and in peaks 
associated with nucleic acids (Figure 5.9, left). This is similar to what we have previously reported 
(Chapter 3) and highlights the proliferative activities of E2 on MCF-7 cells (20). However, in the samples 
that had ERα knocked down, this signature is lost and there is no clear distinction between E2 and 
vehicle treatment (Figure 5.10). There are two cells with higher absorbance in the C-H stretching region 
(Figure 5.10, left), and this could be a result of the low knockdown efficiency. The overall trend in this 
region, however, is similar to what was seen in the bulk IR measurement (Figure 5.3). After 72h of 
recovery from knockdown, the signature has returned in the MCF-7 cells, due to the reestablished level 
of ERα at this time which was confirmed by western blot (Figure 5.1). 
 
Figure 5.7: The Amide I peak can be used to distinguish the cell body of MCF-7. It is not affected by knockdown or treatment. 
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Figure 5.8: The peak at 1236 cm
-1
 is not affected by knockdown, but it is changed in cells treated with E2. 
 
  
Figure 5.9: In control samples, E2 induces an increase in peak height in the C-H stretching region (right) and in peaks 
associated with nucleic acids (left) in the nucleus of MCF-7 cells. These results confirm what we have previously reported. 
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Figure 5.10: In knockdown samples, however, there is no distinct separation of samples after E2 stimulation. 
  
Figure 5.11: After 72h of recovery from the knockdown, the signature has returned. 
ERα expression correlates with IR data in patient samples 
Next, we wished to determine if there were differences in the spectra of breast tumor tissues 
with different levels of ER expression. We chose twenty cores from patients with stage II/III invasive 
ductal carcinoma from a breast tissue microarray containing several different stages and levels of ER 
expression (8,21). Ten cores were from patients with low (<20%) ER expression and ten cores were 
from patients with high (<80%) ER expression, as determined by immunohistochemical staining and 
the pathology report. Each set of ten cores came from 5 patients. Patient characteristics are summarized 
in Table 5.1. The cores were scanned as previously described in Chapter 3 and a Bayesian classifier was 
used to extract pixels from the epithelial cells only. When the spectra were compared for the cumulative 
average of each core set, only subtle differences were observed (Figures 5.12 and 5.13). There is a slight 
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increase in absorbance at the 1080 cm-1 peak in cores with high ER expression (Figure 5.14). Analysis of 
the second derivative spectra in the 1500 – 950 cm-1 region reveals that there are more substantial 
differences than upon visual inspection of the raw averages, particularly in peaks associated with the 
methylene (-CH2-) of fatty acids and aromatic C=C, perhaps indicating a snapshot of altered metabolism 
in these tissues.  
While the results from the average across all ten samples were discouraging, upon inspection of 
the individual cores we observed striking heterogeneity between the samples (Figure 5.15). The tumors 
were matched for breast cancer subtype, grade, lymph node status, and receptor status to the best of 
our ability, all tumors were grade II or III and were not regionally invasive or metastatic (Table 5.1). 
Using IR, we detected significant changes in the global biochemical picture of the epithelial cells in these 
tissues. There is heterogeneity in all regions of the spectrum across cores and even between cores from 
the same patient (Figures 5.16 and 5.17). To determine if IR can detect any similarity between the 
tissues, the second derivative was taken for the average spectrum of each core and these data were 
subjected to an unsupervised clustering analysis (Figure 5.18). Samples were clustered using a 
correlation metric for both rows and columns and four patient clusters were observed. Surprisingly, not 
all cores from the same patient were clustered together (Low 1/2, Low 3/4, and High 9/10 were in 
different clusters). Samples Low 2 and Low 3 were clustered with cores expressing high ERα levels. The 
matched cores come from different regions of the same tumor, so this heterogeneity may be due to 
differences in the tissue characteristics in these cores. It is possible that one core captures a tumor 
margin while the other does not. The histology of these cores should be investigated further and 
another tissue dataset should be used to confirm these preliminary results. 
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Figure 5.12: Average spectra for 10 IDC cores with high ERα expression and 10 IDC cores with low ERα expression. There is 
very little difference between the two sets. 
 
Figure 5.13: In the C-H stretching region, there are peak shifts observed between high and low expression. 
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Figure 5.14: The most apparent differences are in the peaks associated with nucleic acids as well as at 1450 cm
-1
 (methylene 
–CH2- and aromatic C=C). 
 
Figure 5.15: Average second derivative spectra of the two classes reveals significant differences in the 1450, 1400, and 1350 
cm
-1
 peaks. 
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Table 5.1: Summary of patient characteristics. 
Sample ID Age Grade ER PR Her2 TNM 
Low 1/Low 2 59 II/III +, 5% ++, 50% borderline T2N0M0 
Low 3/Low 4 40 II +, 5% +, 5% moderate T2N0M0 
Low 5/Low 6 76 II ++, 5% none weak T2N0M0 
Low 7/Low 8 39 II/III +, 5% weak positive T2N0M0 
Low 9/Low 10 53 II/III ++, 15% none none T3N0M0 
High 1/High 2 32 II ++~+++, 80% ++, 50% weak - 
moderate 
T2N0M0 
High 3/High 4 48 II/III ++~+++, 80% ++, 15% moderate T2N0M0 
High 5/High 6 53 II ++~+++, 80% none positive T2N0M0 
High 7/High 8 70 II +++, 90% ++~+++, 95% weak T2N0M0 
High 9/High 10 68 II/III ++~+++, 80% none none T3N0M0 
 
  
Figure 5.16: There is a significant degree of variability even within the individual classes in the C-H stretching region. 
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Figure 5.17: There is a considerable degree of heterogeneity between samples. 
 
 
Figure 5.18: Cluster analysis of the second derivative reveals four clusters of samples, with only two samples misclassified 
based on ERα expression. 
Discussion 
We aimed to develop a label-free chemical imaging based signature of ERα presence, 
localization, and function using FT-IR spectroscopic imaging. We used MCF-7 cells, a tumorigenic ER+ 
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human breast cancer cell line as a model system for this study. A recent report has used FT-IR to 
discriminate between ER+ (MCF-7) and ER- (SKBR3) cell lines (22). However, we aimed to directly 
compare cells with differing levels of ERα from the same parental line. Thus, we compared wild-type 
MCF-7 with those that had been transfected with siRNA against the ERα protein. We also analyzed the 
spectra of human tumor biopsies expressing different levels of ER, as determined through 
immunohistochemistry.  
We found that in bulk measurements, absorbance in the peaks of the C-H stretching region and 
in peaks associated with nucleic acids was decreased, confirming our previous results (Chapter 3). These 
results highlight the nature of ERα activity in ER+ breast cancer cells. ERα promotes metabolic activity 
and proliferation; the anti-estrogen tamoxifen has been used to therapeutically block this activity 
(23,24). There are challenges associated with gleaning diagnostic information from bulk measurements, 
however. Any result obtained from these studies is the average of a collection of hundreds or thousands 
of cells. Cells endogenously express different levels of protein, and knockdown efficiency is not 100%. 
Hence, in this experiment we aimed to further describe a spectroscopic signature at the level of 
individual cells. 
It is known that upon treatment with estradiol (E2), ERα is translocated to the nucleus (19). 
Therefore, we used FT-IR image analysis to look for a signal of ERα in the nucleus of MCF-7 cells upon E2 
treatment. We compared these signals to MCF-7 that had been transfected with siRNA against ERα and 
then treated with E2. We described a signature of ERα activity that is consistent with our previous result 
of the bulk knockdown measurements. Further, we find that after 72h of recovery from knockdown, the 
signature is restored. These observations confirm that this signature is the result of ERα activation and 
its downstream metabolic and proliferative effects. 
While these findings from in vitro studies are important for understanding the correlations 
between expression of an active receptor and a label-free signature, E2 challenges are not done with 
patients to determine hormone response. To move towards a diagnostically-relevant finding, we 
examined the IR spectra of patient breast tumor samples. We compared tissues from patients with 
invasive ductal carcinoma with low ERα expression to those with high ERα expression. We found that 
when samples from patients were averaged, there were no apparent differences in raw absorbance 
spectra between the two groups; however, second derivative analysis revealed differences in several 
peaks in the 1500 – 1300 cm-1 region. When samples were looked at individually, the spectra were very 
heterogeneous, even between samples from the same tumor. Samples were classified based on the 
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second derivative of normalized average spectra with fair concurrence to ERα expression level; only two 
samples were clustered outside of their hormone status classification. These results indicate that FT-IR 
image analysis can be used to detect heterogeneity that may not be apparent with histology and 
highlight the necessity for an expanded study of additional patients with treatment and outcome 
information.  
In conclusion, we show that estrogen receptor-α, a potent biomarker and prognostic factor for 
the majority of breast cancers can be detected using FT-IR imaging. These exciting results demonstrate 
that FT-IR could be used to show the function of estrogen receptor in fixed samples as a complement to 
immunohistochemical staining in the future. 
Materials and Methods 
Cell Culture 
MCF-7 were grown as previously described (25) in MEM (Signal-Aldrich Corp., St Louis, Missouri, 
USA) supplemented with 5% calf serum (HyClone, Logan, Utah, USA), 100 µg/ml penicillin/streptomycin 
(Invitrogen, Carlsbad, California), and 25 µg/ml gentamycin (Invitrogen). Cells were either grown in 10 
cm tissue culture plates or directly on IR-transmissive CaF2 windows (International Crystal Laboratories, 
Garfield, New Jersey) or IR-reflective MirrIR slides (Kevley Technologies, Chesterland, Ohio, USA). Cells 
were seeded in a hormone-depleted medium consisting of phenol red-free MEM containing 5% 
charcoal-dextran-treated calf serum.  Cells were grown in this medium for five days prior to knockdown, 
and medium was changed on the second and fourth days of culture.  
Knockdown and Treatment 
 Endogenous ERα was knocked down using an siRNA duplex against the F-domain of ERα as 
previously described (18). siRNA was transfected at a final concentration of 50 nM using the 
DharmaFECT transfection reagent (Dharmacon, Lafayette, Colorado, USA) as per the manufacturer’s 
recommendations at 72h before ligand treatment. The siERα forward sequence is 
UCAUCGCAUUCCUUGCAAAdTdT and the reverse sequence is UUUGCAAGGAAUGCGAUGAdTdT. After 
72h of knockdown, some samples were treated with ligand. To establish a gradient of ERα expression, 
the media was changed on the remaining samples and after 24, 48, or 72h of growth to re-establish ERα 
protein, these samples were treated with ligand. Cells were treated with 10 nM estradiol (E2) or the 
same volume of ethanol (Veh) for 24 hours prior to fixation or protein isolation. 
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Western Blot Analysis 
 Whole-cell extracts were prepared using ChIP buffer (10 mM EDTA, 50 mM Tris buffer, 0.5% 
Empigen BB, and 1% SDS) supplemented with 1 x complete protease inhibitor (Roche, Basel, 
Switzerland). Proteins were separated on a 4-20% SDS-PAGE gel and transferred to a nitrocellulose 
membrane. The primary antibody used was mouse anti-ERα (clone F-10, Santa Cruz Biotechnology, 
Dallas, Texas) diluted 1:100 in Odyssey blocking buffer (Li-Cor, Lincoln, Nebraska). The secondary 
antibodies used were goat anti-mouse 800CW (Li-Cor) and goat anti-mouse 680 IRDye (Li-Cor) at a 
dilution of 1:10,000 in Odyssey blocking buffer. Load control was mouse β-actin (Signa-Aldrich Corp). 
FT-IR imaging 
 For cell fixation for IR imaging, the medium was removed and samples were washed three times 
in 1X PBS followed by washing three times in MilliQ water. Cells were fixed in 70% ethanol for 20 
minutes. Samples were washed again 3 times in MilliQ water and then dried completely in a biosafety 
cabinet.  
 Imaging was done in ATR mode using a PerkinElmer Spotlight 400 FT-IR Imaging System as 
previously described (8). Briefly, three independent 150 µm x 150 µm regions of each sample were 
measured using 8 cm-1 spectral resolution with 16 co-additions. A background was taken with 8 cm-1 
spectral resolution and 120 co-additions. The pixel size was approximately 1.56 µm x 1.56 µm. Images 
were atmospheric corrected and an ATR correction was done on the instrument. Data was processed 
using ENVI-IDL. First, a minimum noise fraction (MNF) reduction technique was used to minimize 
sources of noise. Then, the images were baseline corrected and regions of interest were drawn around 
each individual cell. Average spectra of the nuclei were taken by thresholding the 1236 cm-1 peak. 
Breast cancer biopsy tissue 
 A breast cancer microarray (BR961, US Biomax Inc., Rockville, Maryland, USA) containing 
normal, non-malignant, and invasive carcinoma samples with varying levels of ERα expression was 
mounted on an IR-transmissive BaF2 window and imaged as previously described (8). The corresponding 
immunohistochemistry stained sections were marked for ERα expression by a pathologist and cores 
were divided into high expression (>80% of cells with nuclear ERα) or low expression (1-20% of cells with 
nuclear ERα). A Bayesian classifier was used to extract pixels from the epithelial cells only (21), and 
average spectra were taken of individual cores for comparison.  
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CHAPTER SIX: SUMMARY, IMPLICATIONS, AND FUTURE DIRECTIONS 
 
We have demonstrated a new systems pathology approach for studying early breast cancer 
progression by combining three-dimensional cell culture models, molecular profiling, and chemical 
imaging. We investigated how fibroblasts affect breast cancer cell phenotypes, in particular the 
induction of an epithelial-to-mesenchymal transition (EMT) and hormone-independent/endocrine 
resistant growth. We characterized the soluble factors that govern cross-talk between cancer cells and 
fibroblasts using protein array profiling, and found that this secreted protein signature can be used to 
classify breast cancer patients based on the corresponding gene expression profile (iSig). Further, we 
have defined label-free chemical signatures of cellular transformations using Fourier transform infrared 
(FT-IR) spectroscopic imaging. Our approach incorporates the fields of cell biology, molecular biology, 
chemistry, and engineering with applications to medicine. These exciting results highlight the necessity 
for novel approaches in studying cancer progression, and we propose the use of emerging imaging 
technologies and proteomics to translate results from cell culture to patient samples for a more direct 
and lasting impact. To continue with the work discussed here, we will optimize our approach to continue 
the translational activities described herein.  
Future Directions 
This work has direct implications in the following areas: 
1. Development of three-dimensional co-cultures for high throughput analysis and drug testing. 
While we and others have demonstrated the utility of three-dimensional cell cultures for 
studying cancer phenotypes and mimicking human disease states, our work highlights the importance of 
including additional cell types. We have shown that fibroblasts significantly alter the activities and drug 
responsiveness of breast cancer cells. Additional cell types to add in the future for studying breast 
cancer are macrophages, myoepithelial cells, adipocytes, and lymphocytes. We propose to take the 
static cultures developed in this work and engineer environments to parallelize experiments. Two 
technologies that will enable this have recently been described for use in the cancer field. Microfluidic 
devices can be used to study living cells and run parallel experiments and assays on one device. Three-
dimensional printers can be used to print hydrogels containing different cell types in any type of 
designed environment. These three-dimensional cultures and devices can be used to study cell-cell 
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interactions and also to screen small molecule libraries and test drugs. In the future, a patient’s own 
cells could be printed in an environment that exactly recapitulates the patient’s own histology and these 
constructs could be used for drug testing.  
 
2. Using protein profiling for early prognostics. 
We have shown that the interaction between cancer cells and fibroblasts can be characterized 
by the profile of secreted proteins. We took this signature and derived a corresponding gene signature, 
termed iSig. Using this approach, we were able to classify breast cancer patients based on their 
expression of iSig. An important next step in determining key factors that differentiate patients will be 
to use bioinformatics approaches to narrow down the signature from a 46-protein signature to a smaller 
subset of proteins. Gene set enrichment analysis (GSEA) is a tool used in bioinformatics for the 
assessment of gene signatures and how they relate to different populations using publicly-available 
microarray data. By performing hierarchical clustering of both the iSig and patients, we may be able to 
determine which genes/proteins may play a role in early disease progression. By identifying those early 
factors, we can design inhibitor studies to reverse the phenotype in cell culture for potential therapies. 
Perhaps more importantly, the proteins we identified are secreted and there is the potential for them to 
be detected in the bloodstream. There is the potential to prune the secreted protein signature and 
develop a biomarker or set of biomarkers to monitor disease status. A so-called liquid biopsy could be 
used to detect disease progression or treatment failure in patients. Eventually, a blood test could be 
developed as a screening tool based on the same principles. 
 
3. Using FT-IR to determine breast cancer phenotypes and improve histology for modernized pathology.  
FT-IR is a powerful imaging technique that can detect subtle chemical changes in heterogeneous 
samples. We identified a label-free spectroscopic signature associated with response to hormones and 
used this signature to translate results from cell culture to patient samples. In order to develop IR as a 
diagnostic tool, an expanded study should be done that correlates the information from an initial biopsy 
with treatment and outcome. An expanded study will determine whether IR imaging can be used to 
predict long-term endocrine sensitivity. This information could provide the pathologist with an 
additional layer of information and improve histology-based diagnosis and prognosis for cancer.  
